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Tumor specific drug delivery has become increasingly interesting in cancer 
therapy, as the use of chemotherapeutics is often limited due to severe side 
effects.  Targeted chemotherapy for cancer treatment offers a great potential 
advantage in tumor treatment due to greater specificity of delivery, which leads to 
an increased dose of the cytotoxin delivered to the malignant cells relative to 
healthy cells in the rest of the body. There are two general directions in 
anticancer drug delivery that focus on achieving a high local drug concentration 
specifically in the cancerous tissue while reducing its uptake in healthy cells. i) 
Site-specific delivery can be achieved by conjugating the drug or coating the 
delivery vehicle (liposomes, micelles, etc.) with ligands or antibodies that target 
overexpressed receptors in the tumor tissue. This could also possibly be used to 
direct a drug away from the body sites that are sensitive to the toxic action of the 
carried drug (site avoidance). ii) By incorporating an active and site-specific 
release mechanism within the prodrug or delivery vehicle, it is possible to 
increase the release and therapeutic efficacy of the cytotoxic agent. A 
chemotherapeutic drug delivery system designed to combine these two principles 
(site–specific targeting and site-specific triggering) will fulfill Paul Ehrich’s vision 
of a magic bullet in the treatment of diseases there by overcoming the selectivity 
problems of conventional chemotherapy.  
The folate receptor (FR) is a potentially useful biological target for the 
management of human cancers. Owing to the overexpression of the FRs on the 
surface of malignant cells, conjugation of the cytotoxic agent to folic acid (FA) via 
xxi 
 
suitable spacers has demonstrated the enhanced selective drug delivery to the 
tumor site. Furthermore the degree of over-expression has been found to 
correlate with the stage of tumor growth. Various FA-conjugated prodrugs and 
folate targeted delivery vehicles have been synthesized and are currently in 
preclinical and clinical trials. Biotin (vitamin B7) is also an essential cellular 
micronutrient responsible for various normal cellular functions, and its receptors 
are overexpressed in various cancer cell lines. It has been suggested that the 
sodium dependent multivitamin transporter (SMVT) is responsible for the uptake 
of biotin. It has also been indicated that there has been a higher expression of 
SMVT in several lung, renal, colon and breast cancer cell lines than FR. Several 
biotinylated anticancer agents have also been used in the selective delivery to 
cell lines overexpressing the SMVTs. Most of the folate and biotinylated 
conjugates are equipped with release mechanisms that rely on intrinsic activating 
agents such as small changes in temperature, pH differences, enzyme and an 
external activating tool such as light triggered release (light of shorter 
wavelengths). The use of light of longer wavelengths with better tissue 
penetration to active release of the drugs is warranted, which then will lead to the 
search for novel singlet oxygen photocleavable linkers.  
To address this issue, our lab has screened various olefins and identified vinyl 
diether linker as a potential singlet oxygen-mediated photocleavable linker that 
can be cleaved with a fast rate and in the presence of a photosensitizer (core-
modified porphyrin). The reported synthetic schemes were for symmetric 
molecules with lengthy reaction steps and some reaction conditions not being 
xxii 
 
functional group tolerant. Herein, the chemical synthesis (synthetic scheme) and 
kinetic studies of vinyl diether and some nitrogen and sulphur analogs will be 
described. The potential application of the vinyl diether linker to the synthesis of 
the biological active molecule was not achieved due to high instability of the 
linker in the presence of light. Hence we turned our attention to the alternative 
linker, the aminoacrylate linker, which could be synthesized with high yields and 
was functional group tolerant. 
A multifunctional drug delivery system constituted of the folate (or biotin) linked to 
the photosensitizer (phthalocyanine) by PEG and combretastatin A-4 linked to 
the photosensitizer by a photolabile linker (aminoacrylate) was designed and 
synthesized, and biological activity of six conjugates were determined. The 
conjugates were prepared through straightforward and versatile synthetic routes. 
The evaluation of cell specificity was examined using colon 26 cells that 
overexpress both the folate receptors and biotin receptors. Three of the 
conjugates (FA-PEG2K-PC-CA4, Biotin-PEG897-PC-CA4 and FA-PEG897-PC-
CA4) exhibited high specificity in the in vitro test conducted and in vivo imaging 
using the colon 26 cells. Preliminary in vivo PDT indicated tumor shrinkage after 
the irradiation with two of these conjugates: FA-PEG2K-PC-CA4 and Biotin-
PEG897-PC-CA4. (Data not included in the thesis)  
The ability of the multifunctional prodrugs of optical imaging and treatment by a 
combination of PDT and local chemotherapy could possibly lay the foundations 







Chapter 1: Introduction  
Cancer is one of the most devastating diseases in America and worldwide with 
an estimated 16 million new cases expected per year globally by 2020.1,2 Cancer 
remains a challenging disease to combat because cancer cells share many 
common characteristics with the normal cells from which they originate.3 Despite 
significant progress in the development of anticancer technologies (involving 
tumor detection, prevention, surgery and chemotherapeutic treatments) there is 
no efficient cure for patients with malignant diseases. Thus, current methods for 
diagnosis of cancer often reveal the malignant tissue only after it has already 
metastasized to other parts of the body.4 The main treatment at this stage is 
chemotherapy, which usually can have marginal efficacy due to dose-limiting 
toxicities, inadequate potency, rapid clearance from the body, poor aqueous 
solubility and compromised in vivo stability.5 To limit the onset of severe side 
effects, anticancer chemotherapeutics are often given at suboptimal doses which 
hamper their ability to reach tumor-destroying drug concentrations while 
prompting after prolonged treatments, prompting the development of resistance 
phenomena. Moreover, chemotherapeutic drugs also display a high degree of 
toxicity against normal tissues that show enhanced proliferation rates such as the 
bone marrow, gastrointestinal tract, and hair follicles.6,7 Thus, minimally invasive 
novel cancer treatment modalities that can have selective therapeutic action at 







1.1. Photodynamic Therapy (PDT) 
 Photodynamic therapy (PDT) is a clinically approved, minimally invasive 
treatment modality that can induce cytotoxic effects in tumor tissues with some 
selectivity.8 Selectivity can be achieved by focused irradiation to tumors and by 
using photosensitizers that preferentially accumulate in tumors.9-11 Currently, 
PDT is applied for the treatment of different types of solid tumors as well as some 
non-cancerous diseases such as age-related macular degeneration, 
endometriosis12 and microbial infection.8,13  
1.1.1. Mechanism of PDT 
Unlike conventional cancer treatments, PDT does not cause major systemic 
toxicity. It enables the selective destruction of malignant tissues due to specific 
interaction of three individual non-toxic components a photosensitizer (PS), light 
(600-800 nm) and molecular oxygen.14 Clinically the PS is administered into 
patients intravenously, intraperitoneally or topically. At some time interval after 
the PS administration, the majority of it is cleared from most body tissues but 
retained mainly in tumor, skin and organs of the reticuloendothelial system.15,16 
Upon the irradiation by light of appropriate wavelength mostly from laser source 
or light emitting diode, photosensitizers are excited to the first singlet state (S1) 
(Figure 1). The absorbed energy can be released as heat, emitted as 
fluorescence (utilized for cancer diagnosis) or may undergo an intersystem 






may also be released as heat and/or light (phosphorescence) or be used in 
photochemical or photophysical reactions to form reactive oxygen species 
(ROS). 
 
    Figure 1. Modified Jablonski diagram.17 
The triplet state may react in two ways. In what is known as type I mechanism, 
the excited photosensitizer reacts with substrate molecule through a hydrogen-
atom abstraction or electron transfer reactions to yield free radicals and radical 
ions that react with molecular oxygen, and produce reactive oxygen species 
(ROS) such as superoxide, hydrogen peroxide and hydroxyl radicals. ROS are 
thought to play an important role in an increasing number of physiological and 






direct transfer of the energy of the excited triplet photosensitizer to molecular 
oxygen to generate singlet oxygen another ROS. Generally type I reactions occur 
at low oxygen (hypoxia) and high substrate concentrations while type II reactions 
occur in oxygenated environments.18 The photodynamic generation of reactive 
oxygen species, especially singlet oxygen, to damage the target disease is the 
base of cancer treatment known as photodynamic therapy (PDT).19-22 Singlet 
oxygen is known as a main ROS in photoinduced processes of PDT.23,24 The 
ROS then oxidizes amino acids (tryptophan, phenylalanine histidine, and 
methionine), unsaturated fatty acids and cholesterol found in membranes as well 
as nucleic acid (guanine), which leads to cell death.25,26 
  1.1.2. Singlet Oxygen (1O2) 
Singlet oxygen is the main cytotoxic agent in PDT. Although molecular oxygen 
has a double bond, its outermost pair of electrons are in different (π*x and π*y 
antibonding) orbitals and have their spins parallel, which makes the ground state 
a triplet (3∑g).  Furthermore, two other arrangements of these two electrons are 
possible and   result in the presence of two low-lying singlet states (1∑g and 1Δg 
states).  The 1Δg lies only 22.5 kcal above the ground state and has a remarkable 
life time of 1 h in the absence collisions with other molecules,27 while 1∑g is 37.51 
kcal28 above the 3∑g ground state and has a very short lifetime.  It is 1Δg that has 
come to be called singlet oxygen (1O2): it is the only species that lives long 









                           Figure 2. Singlet oxygen MO energy levels 29,30 
1.1.2.1. Generation of Singlet Oxygen 
Singlet Oxygen can be generated in many ways. Although 1O2 is formed in the 
earth’s biosphere by the absorption of visible and ultraviolet light from the sun,31 
which usually leads to the electronic excitation of the molecules (direct 
photoexcitation), this is not practical since the transition is spin-forbidden. Since 
1O2 permeates most organic matter, oxygen is a common quencher of electronic 
excitation of organic matter.30,32,33 The quenching of the triplet sensitizer by triplet 






common and practical method of generating the 1O2 (eq 1).30,34 When the 
molecular oxygen in its ground triplet state interact with an excited 
photosensitizer in its triplet state, an energy transfer by triplet-triplet annilation35 
occurs, which proceeds  an electron exchange mechanism and result in the 
inversion of the outermost electronic spin and pairing in one π*-antibonding 
orbital. Singlet oxygen has also been generated the quenching of a singlet 








                        Figure  3. Equations for the formation of the singlet oxygen 
The singlet oxygen state is difficult to be represented in a conventional orbital 
diagram in which the electrons are in two antibonding orbitals because it is a two-
fold degenerate compared to the triplet ground state molecular oxygen. One 
component has two electrons in different orbitals. This is a stable arrangement 







Figure 4 A.  1Δg (1O2) formation via triplet-triplet annihilation 
 
The other component with both electrons in the same orbital as indicated by the 
wave function is the most unstable species because this destabilizes the 
molecule and may account for the high reactivity of this singlet oxygen species 
(1Δg+).29  
 






The orbital wave function also indicates that both electrons are in the same 
orbital for the 1∑g+ state.29 
1.1.2.2. Photochemical Reactions of 1O2 
 The two principal reactions characteristic of 1O2 are cycloaddition ([2+2] and 
[2+4]) and the ‘ene’ reactions.  
Ene- Reactions: 1O2 reacts rapidly with allylic alkenes to give allylic 
hydroperoxides.39,40 It has been shown that the attack of the singlet oxygen and 
the subsequent removal of the hydrogen occur in a cis-manner.41 
 
Figure 5. ‘Ene’ reactions of singlet oxygen. 42-44 
[2+4]-Cycloaddition Reactions: Singlet oxygenation of arenes and conjugated or 






endoperoxides.45,46 These reactions are examples of the 1,4-cycloaddition of 





         Figure 6. [2+4] reactions of singlet oxygen. 47-49 
 
 [2+2]-Cycloaddition Reactions: 1O2 reacts with electron-rich olefins, alkenes 
without allylic protons or with sterically hindered alkenes to give four-membered 
ring peroxides called 1,2-dioxetanes.50,51 The photooxidation of the alkenes 
proceeds rapidly with visible light, but stops after the consumption of one 







Figure 7. [2+2] Reactions of singlet oxygen. 52,53 
Dioxetanes tend to unstable and decompose spontaneously two carbonyls. 
 
Figure 8. Decomposition of dioxetanes.54,55 
Biologically, 1O2 tend oxidize amino acids in proteins and peptides (tryptophan, 
cysteine, histidine, methionine and phenylalanine), unsaturated fatty acids, 
cholesterol and nucleic acid bases (such as guanine). 






The lifetime of 1O2 varies from one solvent to another. In particular in 
halogenated solvents 1O2 has a longer lifetime than in non-halogenated solvents 
or in aqueous solvents. For example, 1O2 lifetime in CCl4 is 700 us while that in 
non-halogenated solvents is between 10 -100 us, water 2 us and biological 
systems < 0.04 us. An explanation of the variation of lifetimes with solvent has 
been presented by Kearns.56 He has shown that there is correlation between the 
lifetime of singlet oxygen and the infrared spectral properties of solvent. Solvents 
such as water, biological media, alcohols and hydrocarbons with overtones and 
combination bands that absorb strongly near 8000 cm-1of IR spectra region have 
been shown to have a short oxygen lifetime. This suggests the direct conversion 
of the electronic energy from singlet oxygen into the vibrational energy of the 
solvent is predominant in determining the decay of singlet oxygen. There is little 
indication of heavy–atom effect on the lifetime of singlet oxygen.57 
Since the lifetime of 1O2 in cells is short and it has a limited diffusion distance (10-
300 nm) 21,58,59, the 1O2 generated in the irradiated part of the body cannot 
directly damage cells in the unirradiated part. In PDT, it means the source and 
the concentration of oxygen may have a major impact on the 1O2 generating 
capacity and hence the biological activity. The concentration of 1O2 varies from 
one medium to another and from one compartment to another. For example, the 
oxygen concentration at atmospheric pressure in water is 270 µM while that in 
the blood is 68-171 µM and in tissue is 7-34 µM.60 Solid tumors are known to 






selectively generate 1O2 only in particular locations to damage the diseased cells 
while sparing the healthy ones when the light is focused only on those cells. 
Therefore, PDT-induced oxidative damage is highly localized to regions around 
the photosensitizer.62 This specific damage to the targets can also be improved 
by using a targeted delivery system for the photosensitizer to selectively 
accumulate only in the diseased cells.   
1.1.3. Photosensitizers 
Porphyrin or porphyrin-related compounds form the bulk of the PSs used in PDT 
in clinical settings. (Figure 9) Photofrin was the first generation photosensitizer 
approved in 1993 for the treatment of bladder cancer and as prophylactic 
treatment of several others, such as the treatment of early stage esophageal, 
gastric, cervical and lung cancers.10,63. However, this first generation 
photosensitizer had several limitations with respect to its clinical use such as 38,63-
65 composition of undefined mixture of hematoporphyrin derivatives (HpD), 
induction of long-lasting skin photosensitization, a low extinction coefficient at 
wavelengths for optimal tissue penetration and limited selectivity for target tissue. 
Other first generation photosensitizers were chlorine, bacteriochlorin and other 
porphyrins (Figure 9).66 
Second generation PSs were then developed with better features or 
characteristics such as67 single and chemically pure compound, low tendency to 






tissue, no dark toxicity, fast clearance from the healthy parts of the body and 
specific retention in diseased tissues, stability and good solubility in 
pharmaceutically acceptable formulations and in biological media, high 
photostability and fluorescence, strong absorbance in near infrared (NIR) region 
and a minimum absorbance between 400 to 600 nm. PSs with lowest 
absorbance in the range (400 to 600 nm) where daylight intensity is the highest 
will tend to avoid skin photosensitization when used clinically.  Furthermore, 
optimal light penetration into the tissue is favored by strong absorbance in the 
NIR region between 600 to 800 nm (since wavelengths above 800 nm are 
absorbed by water molecules and singlet oxygen generation is suboptimal), 
which thereby results in more efficient PDT when treating deeper seated 
lesions.62,68,69  
Selective accumulation of PS in tumor combined with it controlled light activation 
enables selective destruction of tumor, sparing the neighboring healthy tissue.  
Selectivity of PS for tumor tissues over healthy tissues is thought to be a 
multifactorial process including physico-chemical properties and binding to 
plasma proteins as well as the particular characteristics of tumors such as leaky 
vasculature, low lymphatic drainage, expression of specific enzymes and 
receptors and pH variation. PSs exhibit direct or indirect cell killing, vascular 
occlusion, release of cytokines and the response of the immune system 






  Figure 9 gives the chemical structures of some PSs investigated in clinical trials, 
while Table 1 summarizes the same PSs with their potential therapeutic 
application in oncology.   
References 10,12,63,70-81 
Trade Name Absorption 
wavelength 
Potential  Indications 
Photofrin,  Photogem, 
Photosan, Hemporfin 
630 nm Cervical, brain, Oesophagus, breast, head 
and neck, lung, bladder, superficial gastric 
cancers, Bowen’s disease, cutaneous 
Kaposi’s sarcoma 
Foscan 652 nm Oesophageal, prostate and pancreatic 
cancer, advanced head and neck tumors 
Visudyne 689 nm Basal and squamous cell carcinomas 
Photochlor 665 nm Basal cell carcinoma, Oesophageal 
cancers, head and neck tumors 






BOPP 630 nm Malignant gliomas 
Pc 4 675 nm Cutaneous and Subcutaneous lesions 
from diverse solid tumor origins 
CGP55847 670 nm Squamous cell carcinoma of upper 
aerodigestive tract 
Photosens 675 nm Skin, breast, lung, oropharingeal, breast, 
larynx, head and neck cancers, Sarcoma 
M1, epibulbal and choroidal tumors, eyes 
and eyelis tumors, cervical cancer 
Purlytin, 
Photrex 
659 nm Kaposi’s sarcoma, cutaneous metastatic 
adenocarcinomas, prostate, brain, lung 
cancers, basal cell carcinomas 
NA 515 nm Breast, myeloma, non-melanoma skin 
cancer 
Levulan 630 nm Skin tumors, head and neck, 







 375- 400 nm Brain, head and neck and bladder cancer 
photodetection 
Talaporfin, laserphyrin 664 nm Solid tumor, lung cancer, cutaneous 
malignancies 
Lutex 732 Prostate, cervical, breast, brain cancer, 
melanoma 
 























1.2. Receptor-Targeted Drug Delivery 
Receptor-mediated drug delivery has two advantages over conventional 
nontargeted therapies. 1) It can enhance net drug up-take by pathologic or 
diseased cells. 2) It reduces drug deposition into nonmalignant cells, which 
therefore reduces the collateral toxicity to normal cells. Differences in the 
structure and behavior of normal and tumor tissue could be used for designing 
drug delivery system facilitating tumor-specific delivery of drug or prodrug and 
specific activation. Generally three targets for the delivery of anticancer drugs in 
drug delivery research have been identified–tumor vasculature, extracellular 
space in the tumor tissue and tumor cells.  
Targeting techniques are classified into passive targeting and active targeting. 
Tumor vasculature continuously undergoes angiogenesis to provide the blood 
supply that feeds the growing tumor.82 High molecular weight molecules and 
other nanoparticles will accumulate in solid tumors at much higher concentrations 
than in normal tissues or organs due to enhanced permeability and retention 
(EPR) effect. Passive targeting is achieved in this case by EPR effect as a result 
of leaky vasculature and limited lymphatic drainage, which is found in tumor 
tissues but absent in normal tissues.83-85 An example of such a targeting 
technique is Doxil. This is a polyethylene glycol (PEG)-modified liposome 
containing doxorubicin (DOX).86,87. Although this technique is useful in cancer 






drugs.88 Hence, there is need for the development of drug delivery systems with 
both passive and active targeting capabilities.   
Certain antigens and receptors are known to be aberrantly up-regulated on the 
surfaces of cancer cells compared to those of normal cells. The tumor antigen- or 
receptor-mediated approach has been largely exploited to enhance the selective 
delivery of cytotoxic agents or imaging probes to target tumors. Therefore, to 
actively target such receptors or antigens, chemical modification of drug carriers 
with tumor targeting ligands such as sugars,89 transferrin,90 antibodies,91 
peptides92,93 and folic acid94 is used. The other receptors devoted to the transport 
of vitamin B12,95 biotin,96,97 and riboflavin98 have been quite recently introduced 
as methods for targeted drug delivery. Of these ligands, FA is one of the most 
widely used because of the advantages. The concept of active targeting consists 
in grafting a molecule ( termed ‘promoiety’) onto an active drug molecule that will 
help it in reaching the pharmacological target, while ensuring that the promoiety 
can afterwards be removed to regenerate the biologically active compound.99 
1.2.1. Folate Receptor-mediated drug Targeting 
Folic acid (FA) is natural vitamin B9 with molecular weight of 441 g/mol that plays 
an essential role in cell survival. It is a vitamin required for a one carbon transfer 
reaction in several metabolic pathways. Rapidly proliferating cells consume the 
vitamin in elevated levels because it is essential for the biosynthesis of the 






transportation of the folate across the plasma membrane in normal cell cells 
under physiological conditions using membrane associated-proteins viz, the 
reduced folate carrier or the folate receptor. The reduced-folate carrier100 is the 
major route of reduced form of vitamin (5-methyl-tetrahydrofolate) entry into 
nonmalignant (normal) cells and will not transport folate conjugates of any type 
under physiological conditions. 
The folate receptor (FR), a 38 kDa glycosylphosphatidylinositol (GP1)  anchor 
glycoprotein101, exists in three isoforms102 namely FR-α, FR-β, and FR-γ. Among 
them, the FR-α is often up regulated on cell surface of a wide variety of human 
carcinomas, which include ovary, brain, kidney, breast, colon, myeloid cells and 
lung malignancies, but it is rarely expressed on most normal cells. FR- β is 
expressed on activated macrophages and on the surface of malignant cells of 
hematopoietic origin. The over expression of the folate receptor on the cancer 
cells perhaps enable the malignant cells to compete successfully for the vitamin 
when supplies are limited.103,104 The inability of folate conjugates to penetrate the 
reduced–folate carrier greatly contributes the low toxicity of folate-linked 
therapeutic agents to normal cells. The FR is significantly upregulated on many 
cancer cells compared to their non-transformed counterparts, and the FR-α 
density also appears to increase as the stage of the cancer increases.104 Taken 
together, it is conceivable that the more advanced stage, the higher grade, and 
chemotherapy-resistant cancers, i.e. the tumors that are most difficult to treat by 






by folate-linked drugs.  An additional correlation has been reported between the 
degree of expression and resistance to standard chemotherapy.105 Since the 
folate receptors bind folic acid with nanomolar affinity 106 (Kd  ~ 0.1- 1.0 nmol/L) 
and transport the captured vitamin into the cell by receptor-mediated 
endocytosis,107 the striking consequence is that those FRs over expressed by 
cancer cells can be selectively be exploited for specific delivery of folate-linked 
drugs into the cancer cells.98  Further reasons for the attractiveness of FA as a 
ligand for FRs are that it is stable and compatible with a variety of organic and 
aqueous solvents, inexpensive, a generally poor immunogenic chemical 
endowed with high affinity for FRs that enhances the differential specificity of 
therapeutic and imaging compounds/particles by targeting folate receptor positive 
cells and can easily be linked to a variety of molecules.108  
FA conjugates covalently linked via folate’s γ-carboxyl moiety to target tumor 
cells maintain a high affinity for the FRs, and their cellular uptake mechanism by 
FRs is as effective as that displayed by FA in its free form.109 Folate conjugates 
enter cells by FR-mediated endocytosis and move through the organelles, and 
deliver their carried cargo to the cell cytoplasm (cytosol) or deposit them in a 
nondegradative compartment. The drug is then released in the 
endosomes/lysosomes mainly by enzymatic cleavage (owing to the acidic 
environment occurring in lysosomes, pH-dependent drug release has also been 






cell surface, the cellular uptake process of these conjugates can be repeated and 
allow a continuous supply into the cell.         
                                 
                                 Figure 10. Structure of folic acid (FA) 
The success of FR targeting is in the enhancement of the intracellular delivery of 
attached macromolecules such as a large number of folate appended polymeric 
drug carriers (liposomes,111-114, dendrimers,115, polysaccharides,116,117, and 
micelles,118, protein toxins,119,120, viruses,121, antisense oligosaccharides,122-124, 
gene therapy vectors,125-127, imaging compounds and neutron activation 
agents.128-131  
1.2.2. Limitations of Folate-targeted drug delivery 
Folate-mediated targeted delivery of drugs/carriers towards solid tumors seems 
very attractive in solid tumor chemotherapy. Unfortunately, not all cancers over-






that do not have folate receptors will have to use alternative tumor-specific 
ligands if drug therapies were to be used.  
The second and major concern is that not all FR targeting trials were successful. 
Because of the high affinity of folate for its receptor, some conjugates may 
release slowly from the receptor to permit accumulation of the therapeutic dose. 
This problem has been solved by the use of hydrolysable linkers to discharge the 
payload or use of therapeutic agents that are effective in the attached form 
constituted the two possible solutions for this potential problem. The most critical 
issue is how to control the release of free drugs (active forms) from the delivery 
system (inactive drug forms) after cellular uptake (need for extrinsic stimulus) 
since the two possible solutions enumerated above relied on intrinsic stimuli 
(physiological conditions within the tumor microenvironment). 
1.3. Current Drug Delivery Systems 
1.3.1. Dendrimers  
These are uniform spherical (globular) nanostructures (macromolecules) ranging 
from 5-10 nm in diameter. Each dendrimer carrier has an initiator core and arms 
made of repeated monomer subunits that act as branching points. Generation or 
layers are synthesized in multiple reaction steps to add layers of monomers until 
the overall structure reaches the desired size.132 Dendrimers synthesized in this 
way create a structure with multiple functionalities for conjugation of functional 






produce a highly branched macromolecule with a three-dimensional structure 
characterized by interior cavities capable of encasing therapeutic drugs or 
imaging units and reactive terminal groups capable of attaching drugs, dyes, 
and/or a variety of sensors.134 Drug release kinetics controlled through the 
properties of the polymer chains that have been designed to be degraded for 
release of a payload.135 Dendrimeric structures including polyamidoamine 
(PAMAM), 135-137 modified poly(propyleneimine) [POPAM] and aromatic ether-
type dendrimers have been developed  for drug delivery.138 
1.3.2. Liposomes Drug Delivery 
These are spherical vesicles formed by the self-assembly of amphiphilic lipids 
and excipients. Lipids form a bilayer based on hydrophobic interactions in 
continuous parallel packing with the hydrophilic head groups positioned towards 
the aqueous environment. Hydrophilic molecules can be encapsulated in the 
inner aqueous phase while hydrophobic molecules can be carried in the 
hydrophobic domains of the lipid bilayer. The membrane is composed of a 
phospholipid and cholesterol bilayer with an aqueous solution at the core. They 
represent one of the first “nanotechnologies” to enter clinical medicine.139 They 
have been utilized for drug delivery due to their ability to encapsulate or 
sequester DNA or drugs that would normally not enter the intercellular 
compartment. When these molecules are encased in a liposome, they can be 
delivered to cells through diffusion as well as receptor-mediated events. They 






agents, which include small molecule drugs, gene therapies and antisense 
oligonucleotides.140 141  Another example is Doxil, which is a PEGylated liposome 
clinically used to treat multiple types cancer, and is one of the most important 
liposomal drug delivery systems. It consists of a packed PEGylated surface 
loaded with doxorubicin through drug diffusion based on ammonium salt 
gradient.142 The liposomal formulations are able to change surface charge (zeta 
potential) with a change in solution pH. The charge switch at acidic pH results in 
the fusion with the cell membrane during endocytosis uptake and allows escape 
of nanocarriers into the cytoplasm to deliver the therapeutic load.143 Some of the 
challenges posed by the liposomal formulations are instability in the blood 
stream, poor solubility of many drugs in the lipid/ surfactant solution, rapid burst 
release of drug and the severe side effects due to their accumulation in skin 
tissue. Another challenge posed in this formulation system is the difficulty to 
control prolonged drug release kinetics 
1.3.3. Polymeric Micelles 
Micelles are composed of spherical vesicles of lipids or other amphiphilic 
molecules, such as polymers or polyamino-acids that self-assemble into small 
nanoparticles with a hydrophobic core. They have been developed as drug 
delivery carriers for hydrophobic drugs.144,145. Genexol-PM is the first non-
targeted polymeric micellar formulation approved for cancer therapy or metastatic 
cancer breast cancer and NSCL cancer, and in the USA it is in a clinical phase II 






copolymer PDLLA (1.75 kDa)-mPEG (2 kDa) forming micelles with size of ~ 60 
nm and taxol loading of ~ 15%(w/w).146,147 Micellar drug delivery systems are 
also being developed for myriad of anticancer agents using formulations with 
sizes ranging from 10-200 nm using polyamino acids and synthetic 
polymers.148,149  
 
1.3.4. Polymeric Nanoparticles 
Polymeric nanoparticles represent the most effective nanocarriers for prolonged 
delivery. They provide significant flexibility in design because polymers can be 
biodegradable or nonbiodegradable and made synthetically or derived from 
natural sources. Common polymers used include poly (lactic acid)(PLA), dextran, 
and chitosan.150 The polymers are degraded into individual monomers, which are 
metabolized and removed from the body via metabolic pathways.  Degradation 
and drug release kinetics can be precisely controlled by physicochemical 
properties of the polymer such as molecular weight, dispersity index, 
hydrophobicity, and crystallinity.  Hydrophilic polymer such as PEG is usually 
grafted, conjugated or adsorbed unto the surface of the nanoparticle to stabilize 
it, reduce hepatic uptake and improve circulation half-life.   The polymeric 
nanoparticles are now in several stages of preclinical and clinical development 
e.g. drug–loaded polymethacrylate encapsulated nanocapsules have been 






stage of clinical trials. Multiple factors affect the pharmacokinetic behavior, but 
the surface charge, size, shape and stealth properties are the most critical,151.  
1.4. Visible/ near IR light as an external stimulus for controlling the release 
of drugs 
Being an external stimulus with unique properties such as external applicability, 
tenability of intensity, flexibility of wavelength and deliverability via various 
methods, light has been considered as a very important tool for a spatiotemporal 
control of drug release/ activation.152 Its success has been seen the release of 
drugs and bioactive compounds (caged compounds-deactivated forms of drugs 
from bioactive compounds).153 UV and short visible (< 400 nm) light have been 
used for the controlled release of drugs to cultured monolayer cells and skin 
surface or the mucosa.154-156 The major limitation of using light of wavelength 
below 700 is  due to limited tissue penetration ability because of scattering and 
high level of endogenous absorbers such as oxy and deoxy-haemoglobin, lipid 
and water.157 Visible/NIR light (650-900 nm) is desired due to its ability to reach 
deeper tissues for the treatment of deep residing (solid) tumor.  However, due to 
the low energy light, its direct application in drug release is impossible since the 
light energy cannot directly trigger the chemical bond (linker) cleavage often 
required for releasing the drugs.158-162 (This section is an invited book chapter in 







1.5. Specific aims and scope 
The chemical principle underlying PDT is the activation of photosensitizer by light 
to convert triplet state oxygen to singlet state oxygen, which can then react with 
biomolecules to cause cell modification or death. Reactions of singlet oxygen 
with double bonds in biological molecules are either through the 1,4- or 1,2-
cycloaddition reactions or through the ‘ene’-reactions. 1,2-Cycloaddition 
reactions generate two carbonyl fragments through the dioxetane intermediate. It 
is from this basis that singlet oxygen photocleavable prodrug release systems 
have been developed. Following the same idea, we have proposed that a 
photodynamic multifunctional drug delivery platform could be developed to 
release drug molecules bearing either –OH, -NH or –SH functional groups. 
1.5.1 Hypothesis:  
A multifunctional prodrug system made up of a drug molecule covalently 
conjugated via a photocleavable linker could be designed. The active drug can 
be released by cleavage of the linker using singlet oxygen generated by PS upon 
activation by near infrared (NIR) light. This could serve as a new strategy for 
controlling drug-release by NIR that is biocompatible and penetrate deeper tissue 
than UV and Visible light. 






To test our hypothesis, the following specific aims were established. 
- Develop a facile synthetic scheme to model conjugates constituting of two 
different molecules containing -OH, -NH and /or –SH as a common 
functional groups readily encountered in drug molecules that were linked 
via vinyl diether bond or analogs [electron rich-double bonds] based on 
previous screening in our lab. 
- Synthesize a prototype prodrug constituting of a drug and photosensitizer 
using the above chemistry and conduct photophysical and biological 
studies (in vitro and in vivo studies) with the prototype prodrug. 
- Synthesize a multifunctional drug delivery platform constituting of a 
photosensitizer and drug molecule(s), covalently attached using the 
photolabile linker and targeting moiety (folic acid or biotin) on a common 
















CHAPTER 2: FACILE SYNTHESIS OF VINYL DIETHER AND ANALOGS, AND 
PHOTOOXIDATION BY SINGLET OXYGEN 
2.1. Introduction  
Although vinyl diether looks as simple as it is, synthesis of this functional group 
was not easy.  Very little work has been done in the past for the development of 
the vinyl diether linker since it had very little importance until recent 
developments in drug delivery systems that require it. Previous methods are 
limited to symmetric molecules, lengthy steps, low yields, harsh reaction 
conditions and non-stereospecficity (mixture of E and Z-isomers). I will cite only 
the most recent references used for the synthesis of vinyl diether linker and 
monoether monothioether linkers.(This chapter is an already published work by 






1,2-Diphenoxyethene was synthesized from ethylene chlorohydrins in a 7-step 
sequence involving high pressure and temperature by Baganz et al. (1959).165  
The other method for the same compound involved chlorination and 
dehydrochlorination of 1,2–diphenoxyethane was used by Serratosa et al. 
(1979).166 This method is limited for the synthesis of symmetric molecules and 
yields a mixture of E and Z-products in low yields. Bauld et al. (1999) developed 
the most recent method for the preparation of 1,2-diphenoxyethene and 
derivatives involving bromination, followed by stereospecific debromination to 
give either the E- or Z-intermediates. Treatment of the cis- or trans- intermediates 
with n-BuLi, followed by either protonation or methylation, then afforded pure cis 
or trans- 1,2-diphenoxyethene or the corresponding 4,4’-dimethyl derivative. This 
method has a number of problems such as limitation only to symmetric vinyl 
diether molecules, facile electrophilic ring bromination on the phenyl or benzene 
ring para to the ether functionality, lengthy steps, and finally low yields.167 These 
are the methods developed so far for the synthesis of vinyl diether bonds with 
phenolic of aryl alcohols. Methods involving aliphatic alcohols are quite different 
and requires a different approach as shown by Dolphin et al.(2008).168 The only 
synthetic scheme of compounds with unsymmetrical molecules (2-
aryloxyvinyl)phenylsulfanes involving the reaction of phenyl hypchlorothioite with 
vinylaryl ethers was developed by  Bychkova et al. (1984).169 This method 
required harsh reaction conditions. 
Many reaction schemes have been tried to establish the vinyl diether linker, 






olefins have been one of the major hurdles. Here, we describe the first facile 
synthetic approach for the 1,2-diheteroatom substituted olefins (scheme 1). It is a 
versatile, efficient, and stereospecific method in as few as four steps from 
starting materials. We have been able to demonstrate that the chemistry can be 
used for the preparation of both symmetrically and asymmetrically diheteroatom-
substituted olefins from a variety of functional groups such as –OH, -NH, and –
SH (Table2).  The photooxidation of those olefins that were not tested in the 




2.2. Materials and Methods 
All solvents and reagents were used as obtained from Sigma Aldrich and Thermo 
Fisher Scientific unless otherwise stated. All reactions were monitored by TLC 
using 5-17 µm silica gel plates with fluorescent indicators from Sigma-Aldrich. All 
column chromatography was done using 40-63 µm silica gel from Sorbent 
Technologies. NMR spectra were recorded at 25 ºC using a 300 MHz 
Spectrometer (NMR data of E/Z-4 and E/Z-8 were recorded with a 400 MHz 






standards. ESI mass spectrometry was done at Mass Spectroscopy South 
Dakota State University, University of Oklahoma, or University of Buffalo. IR 
spectra were recorded on a BioRad FT-155FT-IR spectrometer (using 
dichloromthane as solvent). Melting points were determined by using a Mel-
temp® Electrothermal instrument. 
2.3. Experimental Section  
	  Scheme 1. General synthetic scheme for vinyl diethers and analogs: A) i) KH 
(55 mmol), 1 (37 mmol) at rt, THF, ~30 min, ii) Trichloroethylene (44mmol) at -78 
oC warm to rt, overnight, B) 2 (7.67 mmol), TMEDA (23 mmol), n-BuLi (23 mmol) 
at -78 oC , 1h to -40 oC, 40 min, Et2O, C) i) Cp2ZrCl2 (20.3 mmol), LiEt3BH (20 
mmol) at rt, THF, 1 h, ii) 3 (10.2 mmol) at rt, 30 min, iii) I2 (20.5 mmol) , 40 min, 




















 L1 = trans-N-(2pyridylmethylene)aniline 
b
 L2 = 2-pyridin-2-yl-benzoimidazole 
c














Table 2. Reaction Products from vinylation reactions at the final step 
 
2.3. Synthesis of Compounds 
2.3.1. Synthesis of 4-((1,2-dichlorovinyl)oxy)-1,1'-biphenyl (2): To a two-
necked, round bottom flask (250 mL) equipped with a magnetic stirrer, pressure 
equalizing funnel and rubber septum was suspended oil free potassium hydride 
(2.20 g, 55 mmol, 1.50 eq) in tetrahydrofuran (THF, 25 mL).  4-Phenylphenol 
(6.30 g, 37 mmol, 1.00 eq) in THF (50 mL) was then added drop-wise with 
stirring for over 20 min via the funnel. After the evolution of hydrogen was 
complete, the orange-yellow slurry was cooled to -78 oC, and then treated with 
drop-wise solution of trichloroethylene (5.8 g, 44 mmol, 1.2 eq.) in THF (25 mL) 
for over 10 min. The cooling bath was removed and the reaction mixture was 
allowed to warm to room temperature (rt) and then maintained for overnight (12 
h). To the dark brown mixture was carefully added water (10 mL) using a syringe 
and then partitioned between water (200 mL) and ethyl acetate (200 mL). The 
organic phase was then washed with brine (200 mL). Extraction of the combined 
aqueous layers was done using ethyl acetate (150 mL x 3). The combine organic 
phases were dried over anhydrous magnesium sulfate, filtered and concentrated 
using the rotary evaporator to give yellowish brown oil. Silica gel (200 g) column 
chromatography was done using hexane as eluent to afford 2 (10.5 g, 85 %) as 






MHz, CDCl3): 7.62-7.54 (m, 4H, HAr), 7.48-7.41 (m, 2H, HAr), 7.39-7.32 (m, 1H, 
HAr), 7.18-7.12 (m, 2H, HAr), 6.00 [s, 1H, HC(Cl)=C(O)] ppm; 13C NMR (75 MHz, 
CDCl3): 153.3, 140.2, 137.8, 128.8, 128.5, 127.3, 127.0, 117.4, 103.9 ppm; IR 
(cm-1): 3105, 3031, 1898, 1658, 1630, 1603, 1585, 1543, 1310, 1203, 1184, 
1107, 1074, 1008, 996, 915, 863, 840, 641, 547, 511; HRMS (ESI) Calculated for 
C14H10Cl2O [M-H]- 263.0031; Found 263.0030. 
2.3.2. Synthesis of 4-(ethynyloxy)-1,1'-biphenyl (3): To a two-necked, round-
bottomed flask (100 mL) equipped with a nitrogen inlet adapter and rubber 
septum was added the vinyl ether 2 (2.0 g, 7.6 mmol, 1.0 eq), anhydrous diethyl 
ether (30 mL), and TMEDA (23 mmol, 3.3 mL, 3.0 eq), and then cooled at -78 C. 
2.5 M n-butyllithium (9.0 mL, 23 mmol, 3.0 eq) was then added drop-wise to the 
reaction mixture for over 5 min. The reaction mixture was then maintained at -78 
C for 1 h and at - 40 oC for 40 min, and then cooled to -78 oC while 10% ethanol 
in pentane (10 mL) was added drop-wise. After 10 min, the reaction mixture was 
then diluted with n-pentane (20 mL) and the washed with saturated solution of 
ammonium chloride (25 mL). The organic phase was later washed twice with 
water (20 mL) and then finally with brine (20 mL), dried over anhydrous sodium 
sulfate, filtered and concentrated to give brown oil. The oil was purified by 
column chromatography with hexane as the eluent to yield 3 as dark brown oil 
(0.84 g, 70 %) that later crystallized out as brown amorphous solid: mp 48-49 oC. 
The compound was placed in a round bottom flask and was flushed with nitrogen 






immediately. 1H NMR (300 MHz, CDCl3): 7.64-7.52 (m, 4H, HAr), 7.48-7.41 (m, 
2H, HAr), 7.40-7.34 (m, 3H, HAr), 2.13(s, 1H, H ) ppm; 13C NMR (75 MHz, 
CDCl3): 155.0, 140.1, 138.0, 128.9, 128.4, 127.4, 127.0, 115.4, 84.5, 33.5 ppm; 
IR (cm-1): 3317( C H), 3029, 2927, 2174( C C), 1606, 1512, 1484, 1208, 
1166, 1062, 1008, 941, 838, 641, 548, 450; HRMS (ESI) Calculated for C14H10O 
[M-H]- 193.0654; Found 193.0651. 
 2.3.3. Synthesis of (E)-4-((2-iodovinyl) oxy)-1,1'-biphenyl (4): To an oven 
dried, two-necked flask (250 mL) under nitrogen and protected from light was 
added Cp2ZrCl2 (5.2 g, 20.3 mmol, 2.0 eq), dry THF (30 mL), and 1M lithium 
triethylborohydride (Super Hydride) in THF (20 mL, 20 mmol, 1.9 eq). The 
mixture was stirred for 1 h where the alkyne 3 (1.97 g, 10.2 mmol, 1.0 eq) was 
added. After 30 min, iodine (2.57 g, 20.3 mmol, 2.0 eq) was added and the 
reaction mixture was stirred for 30-40 min while protected from light. The reaction 
was quenched by diluting with ethyl acetate/hexane (1:1, 50 mL). The diluted 
mixture was then washed twice with saturated solution of sodium bicarbonate 
(150 mL) and the combined aqueous layers were extracted with ethyl 
acetate/hexane mixture (1:1). 10% aqueous sodium thiosulphate (100 mL) was 
used to wash the combined organic phases followed by brine (100 mL), dried 
over sodium sulfate, filtered, concentrated to yellowish slurry which was purified 
by silica gel column chromatography using 100% hexane as eluent (silica gel 
was pretreated with 2.5 % v/v triethylamine) to afford 4 as white amorphous 






4H, HAr), 7.49-7.41 (m, 2H), 7.38-7.32 (m, 1H, HAr), 7.13-7.01 (m, 3H, HAr), 
5.74 (s, 1H, CH=CH, J = 12.2 Hz) ppm; 13C NMR (75 MHz, CDCl3): 155.5, 150.3, 
140.3, 137.0, 128.9, 128.4, 127.2, 126.9, 117.5, 57.9 ppm; IR (cm-1): 3316, 3077, 
3034, 2960, 2924, 2874, 2174, 1643, 1623, 1601, 1515, 1485, 1330, 1307, 1226, 
1186, 1173, 1093, 1008, 919, 854, 837, 697, 579, 549. 
2.3.4. General procedure for Coupling Reactions using trans-N-(2-
pyridylmethylene)aniline (L1): (E)-4-((2-(4-(tert-butyl)phenoxy)vinyl)oxy)-
1,1'-biphenyl (6): An oven dried, three- necked, round- bottomed flask (50 mL) 
equipped with a nitrogen inlet, reflux condenser, rubber septum was repeatedly 
evacuated and back-filled with dry and pure nitrogen, and was then charged with 
CuI (0.09 g, 0.50 mmol), L1 (0.09 g, 0.50 mmol), tert-butyl phenol (0.18 g 1.2 
mmol), and Cs2CO3 (0.81 g, 2.5 mmol), followed by the addition of anhydrous 
and degassed acetonitrile (1.2 mL). The flask was evacuated and back-filled with 
nitrogen and trans - 4 (0.32 g, 1.0 mmol) added at rt. The reaction mixture was 
stirred and heated to the required temperature of 80 oC for the 48 h. After cooling 
to rt, the mixture was diluted with dichloromethane (DCM, 20 mL) and filtered 
through a plug of celite, with the filter cake being further washed with DCM (10 
mL). The filtrate was washed with saturated NH4Cl (15 mL), and twice with water 
(10 mL). The collected aqueous phases were extracted twice with DCM (10 mL). 
The organic layers were collected, dried over MgSO4, filtered, and concentrated 
in vacuo to yield brown solid. The crude product was fixed with 6.0 g silica gel 






solid (0.20 g 65%): mp 59-62 oC. 1H NMR (300 MHz, CDCl3) 7.59-7.52 (m, 4H, 
HAr), 7.46-7.40 (m, 2H, HAr), 7.38-7.33 (m, 3H, HAr), 7.15-7.09 (d, 2H, J = 8.5 
Hz, HAr), 7.02-6.97 (d, 2H, J = 8.6 Hz), 6.91 (s, 2H, CH=CH), 1.32 (s, 9H, 3 x -
CH3) ppm; 13C NMR (75 MHz, CDCl3) 157.2, 155.3, 145.6, 140.6, 135.7, 135.3, 
134.2, 128.8, 128.4, 127.0, 126.8, 126.5, 116.0, 115.3, 34.3, 31.5 ppm; IR (cm-1): 
3052, 2961, 2931, 2867, 1607, 1512, 1487, 1367, 1298, 1229, 1187, 1127, 1105, 
1079, 1006, 839, 723;HRMS(ESI), Calculated for C24H24O2  [M+H]+ 345.1854; 
Found 345.1849. 
2.3.5. Synthesis of (E)-4-[2-(4-methoxyphenoxy)vinyloxy]biphenyl (7): 
Compound 7 was prepared according to the general method described for 
compound 6 above, employing trans-- 4 (0.20 g, 0.62 mmol, 1.0 eq) and 4-
methoxyphenol (0.077 g, 0.62 mmol, 1.0 eq), Cs2CO3 (0.50 g, 1.6 mmol, 2.5 eq), 
CuI (0.59 g, 0.31 mmol, 0.50 eq) and L1 (0.057 g, 0.31 mmol, 0.50 eq) heating 
the reaction mixture at 80 oC for 48 h to furnish the crude product which was 
purified by column chromatography using hexane as the eluent to afford 7 as 
white crystals (40 mg, 40 %): mp 112-115 oC. 1H NMR (300 MHz, CDCl3): 7.61-
7.52 (m, 4H, HAr), 7.47-7.40 (m, 2H, HAr), 7.36-7.30 (m, 1H, HAr), 7.10 (d, 2H, J 
= 8.6 Hz), 7.00 (d, 2H, J = 9.0 Hz), 6.91-6.84 (m, 4H, HAr and HC(O)=C(O)H), 
3.80 (s, 3H, -CH3) ppm. 13C NMR (75 MHz, CDCl3): 156.3, 154.3, 150.5, 139.5, 
135.6, 135.1, 132.7, 131.4, 129.0, 127.8, 127.3, 125.8, 116.1, 115.0, 113.8, 54.7 






1122, 896, 838, 737, 639; HRMS(ESI), Calculated for C21H18O3 [M-H]- 317.1178; 
Found 317.1158. 
 2.3.6. Synthesis of (E)-(2-([1,1'-Biphenyl]-4-yloxy)vinyl)(phenyl)sulfane (8): 
The compound 8 was prepared according to the general procedure described for 
the compound 6 above employing trans- 4 (0.15g, 0.47 mmol, 1.0 eq) and 
thiophenol (0.051g, 0.050 mL, 0.47 mmol, 1.0 eq), Cs2CO3 (0.38 g, 1.2 mmol, 2.6 
eq), CuI (0.044 g, 0.23 mmol, 0.49 eq) and L1 (0.042 g, 0.23 mmol, 0.49 eq) 
heating the reaction mixture at 60 oC for 10 h to give crude product, which was 
purified by silica gel column chromatography (100 % hexane) to give compound 
8, as white crystals (0.12 g, 90 %). [When a mixture of Z and E-4 (1:9) was used 
as the starting material under same conditions at a temperature above 100 oC 
afforded a mixture of Z and E-8 (1:9). They were distinguished from each other 
by their coupling constants. Jcis = 5.7 Hz while Jtrans= 12 Hz (1H-NMR data of 
these mixtures are found below). The characterization data below is that of pure 
8 obtained from the reaction pure 4 with thiophenol: mp 92-96 oC. 1H NMR (300 
MHz, CD2Cl2): 7.66-7.54 (m, 4H, HAr), 7.48-7.40 (m, 2H, HAr), 7.37-7.28 (br s, 
6H, HAr), 7.20-7.09 (m, 3H, HAr), 6.09-6.10 (d, 2H CH=CH, J = 12.0 Hz) ppm; 
13C NMR (300 MHz, CDCl3): 155.9, 150.6, 140.3, 137.5, 137.1, 128.9, 128.8, 
128.5, 127.2, 127.0, 126.9, 125.7, 117.4, 102.1; IR(cm-1): 3054, 2985, 1659, 
1624, 1599, 1515, 1485, 1265, 1233, 1185, 1174, 1112, 1086, 1025, 1007, 924, 







 2.3.7. Synthesis of (E)-N-(2-(Biphenyl-4-yloxy)vinyl)aniline (9) : Compound 9 
was tried to be prepared according to the general methods described for 
compound 6 (and 5) above, employing trans- 4 (0.15 g, 0.47 mmol, 1 eq), aniline 
(0.043 g, 0.47 mmol, 1 eq), Cs2CO3 (0.38 g, 1.1 mmol, 2.5 eq), CuI (0.044 g, 023 
mmol, 0.5 eq) and L1 (0.042 g, .23 mmol, 0.5 eq) at 80 oC to give a new weak 
spot on TLC which might be the product. However, it could not be purified using 
a silica gel column chromatography. 
2.3.8. General procedure for Coupling Reactions using 2-pyridin-2yl-1H-
benzoimidazole (L2): (E)-4-((2-(phenoxy) vinyl) oxy)-1,1'-biphenyl (5): An 
oven dried, three- necked, round- bottomed flask (50 mL) equipped with a 
nitrogen inlet, reflux condenser, rubber septum was repeatedly evacuated and 
back-filled with dry and pure nitrogen, and was then charged with CuI (0.074 g, 
0.39 mmol, 0.5 eq), L2 (0.076 g, 0.39 mmol, 0.5 eq) and Cs2CO3 (0.63 g, 2.0 
mmol, 2.5 eq), followed by addition of DMF (2 mL). The solution was stirred for 
10 min at rt until reaction turn light green color. The appropriate substrate phenol 
(0.073 g, 0.78 mmol, 1 eq) was added to the reaction mixture and then stirred for 
addition 5 min at rt. Trans- 4 (0.25 g, 0.78 mmol, 1eq) was dissolved in minimum 
amount of solvent and then added into the reaction mixture. The reaction mixture 
was then heated from rt to between 50-75 oC for 12-36 hr depending on the 
substrate. The reaction mixture was cooled and then through pad of silica gel 
using ethyl acetate and hexane mixture (20:80, 100 mL) and then washed three 






(100 mL x 3) followed with brine (200 mL), dried using anhydrous sodium sulfate 
and concentrated in vacuo to yield brown oil. The crude oil was then purified by 
silica gel column chromatography using 100% hexane to afford 5 as white 
crystals. (0.18 g, 70 %): mp 60-63 oC. 1H NMR (300 MHz, CDCl3): 7.59-7.54 (m, 
4H, HAr), 7.47-7.40 (m, 2H, HAr), 7.37-7.31 (m, 1H, HAr), 7.16-7.03 (m, 7H), 
6.92 (s, 2H, HC=CH); 13C NMR (75 MHz, CDCl3): 157.6, 157.2, 140.4, 135.8, 
134.9, 134.6, 129.7, 128.8, 128.4, 127.0, 126.9, 122.7, 116.0, 115.8; IR (cm-1): 
3061, 2962, 2870, 1606, 1510, 1485,1419, 1365, 1230, 1183, 1174, 1124, 1105, 
1006, 896, 836, 728; HRMS (ESI), Calculated for C20H16O2  [M-H]- 287.1072; 
Found 287.1053. 
 2.3.9. Synthesis of (E)-1-(2-([1,1'-Biphenyl]-4-yloxy)vinyl)-1H-indole (10): 
The compound 10 was prepared following the procedure described for 5 with 
trans- 4 (0.32 g, 1 mmol, 1 eq), indole (0.14 g, 1.2 mmol, 1.2 eq), Cs2CO3 (0.81 
g, 2.5 mmol, 2.5 eq), CuI (0.095 g, 0.5 mmol, 0.5 eq) and L2 (0.097 g, 0.5 mmol, 
0.5 eq) at 70 oC for 12 hr to give crude product which were purified by silica gel 
column chromatography using ethyl acetate-hexane (9:95) to afford compound 
10 as white crystals (0.27 g, 87 %): mp 140-142 oC. 1H NMR (300 MHz, CDCl3): 
7.58-7.46 (m, 6H, HAr), 7.40-7.32 (m, 3H, HAr), 7.25-7.21 (m, 1H, HAr), 7.20-
7.14 (m, 2H, HAr), 7.12-7.02 (m, 4H, HAr and H(O)C=(N)CH), 6.55 (d, H, J = 3.1 
Hz, HAr). 13C NMR (75 MHz, CDCl3): 156.8, 140.4, 136.5, 136.4, 128.9, 128.8, 
128.5, 127.1, 126.9, 125.7, 125.6, 121.2, 120.5, 116.5, 115.2, 109.8, 104.0 ppm; 






1322, 1301, 1232, 1202, 1186, 1174, 1134, 1115, 1088, 1031, 1007, 907, 865, 
834; HRMS (ESI), Calculated for C22H17NO [M+H]+ 312.1388; Found 312.1381. 
2.3.10 Synthesis of (E)-1-[2-(Biphenyl-4-yloxyl)vinyl]-1H pyrrole (11): The 
compound 11 was prepared following the procedure described for 5 with trans- 4 
(0.2 g, 0.62 mmol, 1 eq), pyrrole (0.062 g, 0.93 mmol, 1.5 eq), Cs2CO3 (0.40 g, 
1.2 mmol, 2.5 eq), CuI (0.059 g, 0.31 mmol, 0.5 eq) and L2 (0.060 g, 0.31 mmol, 
0.5 eq) at 70 oC for 12 hr to give crude product which were purified by silica gel 
column chromatography using ethyl acetate-hexane (9:95) to afford compound 
11 as white crystals (0.14 g, 85 %): mp 102-105 oC. Olefinic protons coupling on 
the named compound gave an AB-system with a typical roof effect with peaks 
centered at 7.04 and 6.99 ppm. 1H NMR (300 MHz, CDCl3): 7.62-7.53 (m, 4H, 
HAr), 7.48-7.40 (m, 2H, HAr), 7.38-7.31 (m, 1H, HAr), 7.17-7.09 (m, 2H, HAr), 
7.04 (distorted d, 1H, J = 11.1 Hz, (O)-CH=CH(N)), 6.99 (distorted d, 1H, J = 11.1 
Hz, (O)-CH=CH(N)), 6.82 (dd, 2H, J1 = 4.2 Hz, J2 = 2.2 Hz, CH=CH of pyrrole), 
6.28 (dd, 2H, J1 = 4.2 Hz, J2 = 2.2 Hz, CH=CH); 13C NMR (75 MHz, CDCl3): 
156.8, 140.4, 136.3, 135.0, 128.8, 128.4, 127.1, 126.9, 119.6, 118.3, 116.5, 
110.0 ppm; IR (cm-1): 3086, 3034, 2715, 2682, 1659, 1607, 1587, 1517, 1485, 
1360, 1326, 1300, 1239, 1229, 1185, 1173, 1119, 1094, 1072, 1056, 1007, 975, 








2.4. General photooxidation procedure: To a 0.5 mL CDCl3 in an NMR was 
dissolved an olefin(0.0048 mmol).. The photosensitizer [5-(4-methoxyphenyl)-
10,15,20-triphenyl-21-23-dithiaporphyrin, CMP-OMe, 3 mg, 0.0048 mmol] was 
added to this solution. Then, the reaction mixture was irradiated for 15 min using 
a diode laser (690 nm, 200 mW/cm2). The reaction of olefins with singlet oxygen 
was monitored by the decrease of olefinic peaks, while the formation of the 
photooxidation products were also measured by the increased in the formate 
peaks in 1H-NMR spectra.  
2.5. RESULTS AND DISCUSSION 
For the synthesis of the diheteroatom-substituted olefins, four-step scheme was 
developed where 4-phenylphenol 1 was used in one side. First, 4-phenylphenol 
was vinylated using 1,1,2-trichloroethylene 170 to give the corresponding 4-((1,2-
dichlorovinyl)oxy)-1,1'-biphenyl 2 with yield of more than 85%.171,172 Then, 4-
(ethynyloxy)-1,1'-biphenyl 3 was prepared by elimination reaction using n-BuLi in 
70 % yield.171,172 Although 1 was used in this paper, other types of alcohols and 
phenols can also be converted to the alkyne form.171 Hydrozirconation and 
iodinolysis of 3 led to 2-iodoenol ether 4 in 55 % yield.173,174 Using the copper-
catalyzed coupling reaction, 4 were linked with various substrates bearing the 
different functional groups.175-177  
The reaction with thiophenol gave the best yield (8: 90%) and short reaction time 






the reaction with phenols (compounds 5, 6, 7). The trend could be explained by 
the relative nucleophilicity of the substracts (-SH > -NH > -OH) (Table 1). Two 
coupling conditions were used; either trans-N-(2-pyridylmethylene)aniline as 
ligand in acetonitrile as solvent 176,178 or  2-pyridin-2-yl-benzoimidazole as ligand 
in DMF as solvent.177 For the compound 5, slightly better yields were obtained 
using the latter coupling condition and the reaction time was reduced to 16 h 
compared to the former condition (36 h). To test the robustness of our method, 
some selected analogues of the phenolic and azole derivatives were synthesized. 
Phenolic derivatives required high temperatures of 70-80 oC for 16-48 h of 
reaction time and yields were poor-good (40-70 %). Further optimization of 
reaction conditions for these low yielding coupling reactions will be pursued. 
Reaction with the azole derivatives required low temperatures between 50-75 oC 
and shorter reaction time, 12 h. The yields for 10 and 11 were very good (87 and 
85 % respectively). Our methodology encountered, however, a limitation in the 
case of aniline. Coupling using aniline substrate gave an extremely low yield that 
the product could not be isolated.  In all of these reactions the products gave 
single isomers (E-1,2-diheteroatom-substituted olefins) since only the trans- 4 
was used for the coupling.177 This is well-known Ullmann-type coupling reaction 
which proceeds in stereospecific fashion.175,177 The stereospecificity of the 
reaction was also supported by the fact that a mixture of E/Z-4 (9:1) at > 100 oC 






Unlike typical coupling constants of 12-18 Hz for protons at E-olefins and 6-12 Hz 
at Z-counterparts, the coupling constants of the hydrogen atoms on 1,2-
diheteroatom-substitituted olefins were found to be reduced and in some cases 
even to zero. Only a peak was observed from 1,2-diaryloxyalkenes (5, 6, and 7) 
where the two olefinic protons are in very similar environment. On the other hand, 
while 8 showed doublet peaks, 11 showed distorted doublet peaks (AB system): 
E-8 (J = 12 Hz), Z-8 (J = 5.3 Hz), E-11 (J = 11.1 Hz). Such unusual small 
coupling constants of olefins were also observed in monohetereoatom-
substituted olefins, especially the oxygen-substituted olefins.175-177 
To examine the oxidation rate of these electron rich alkenes with singlet oxygen 
(Scheme 2), we irradiated compounds 6, 8, and 11 in the presence of 5-(4-
methoxyphenyl)-10,15,20-triphenyl-21,23-dithiaporphyrin as a photosensitizer.179 
All experiments were done following the standard procedure previously set by 
our group with a slight modification by using a 690 nm diode laser source (200 
mW/cm2).180 The 1:1 ratio of olefin and photosensitizer was used to mimic the 
situation of prodrug where the olefinic linker could be used for connecting one 
drug and one photosensitizer (14, 15). The reaction solutions were irradiated for 
15 min and monitored every 5 min using olefinic peaks in 1H-NMR each time to 
monitor the progress of the reactions. Upon the oxidation by singlet oxygen, the 
















Figure 11. Rate of decomposition and formation of cleavage product singlet 
oxygen- mediated oxidation of the heteroatom substituted alkenes 
(E)-1,2-Bis(phenylthio)ethylene was used as a control against which the reaction 
rates were compared. Analysis of the data indicated that not much difference 
exists amongst these linkers with respect to their rate of reaction with singlet 
oxygen (Fig. 11 and Table 3). Double bond peaks of all the four substrates 
disappeared within 15 min of the irradiation. The fast reaction of 6 (1,2-
diaryloxyalkene) and 8 (1-aryloxy-2-arythio-alkene) is consistent with our 
previous report 180. The cleaved formate products 6a, 6b, 8a were formed 
consistent with the decrease of the olefins 6 and 8 (Table 3). On the other hand, 






































oxidized olefin 8, presumably, due to the oxidation at sulfur180. The fast reaction 
of 11 (1-aryloxy-2-amino-alkene) with singlet oxygen was also observed. The 
olefinic peaks of 11 completely disappeared in 10 min. In addition, we also 
observed the decrease of the peaks of protons at the pyrrole ring at a little bit 
slower rate: 73% (olefinic proton) vs. 60% (protons at the pyrrole ring) reduction 
after 5 min. One notable observation is that the formate product 11a was not 
detected in the 1H-NMR from the oxidation of 11. Further investigation is needed 
to reveal the detailed mechanism of oxidation of 11. 
2.6. POTENTIAL FOR BIOLOGICAL APPLICATION 
For our synthetic scheme to be useful we set out to synthesize a model 
compound constituted of combretastatin A4, CA-4, a compound, structurally 
related to colchicines  181 (tubulin-binding agents) which has been shown to 
interact with tubulin 182 and caused vascular shutdown in solid tumors with a 5-(4-
hydroxyphenyl)-10,15,20-triphenyl-21,23-dithiaporphyrin, CMP, (15) as a 
photosensitizer using the vinyl diether linker to give a prodrug, 16, that can easily 
be cleaved using a laser diode or NIR.. Our intention was to get the model 
compound then test it in vitro and subsequently in vivo. The target compound, 16, 
was synthesized but due to its high reactivity, we could not handle the product 









Scheme 3. Proposed scheme for the synthesis of CMP-L-CA4 using vinyl diether 
linker: A) i) KH (0.55 mmol), CA-4 (0.37 mmol) at rt, THF, ~30 min, ii) 
Trichloroethylene (0.44mmol) at -78 oC warm to rt, overnight, B) 12 (0.37 mmol), 
TMEDA (3.65 mmol), n-BuLi (3.65 mmol) at -78 oC, 1h to -40 oC, 40 min, Et2O, 
C) i) Cp2ZrCl2 (0.42 mmol), LiEt3BH (0.42 mmol) at rt, THF, 1 h, ii) 13 (0.23 
mmol) at rt, 30 min, iii) I2 (1.05 mmol) , 40 min, D) 10 mol % CuI, 10 mol % 
ligand, 2 eq. Cs2CO3,  1 eq. 14, 1 eq. 15 , 50-80 oC, 10-48 h 
 
 






2.6.2.1. Synthesis of combretastatin A-4 (CA-4). The compound was 
synthesized as reported in literature.183. 1H-NMR (300 MHz, CD2Cl2): 3.70 (s, 
6H), 3.84 (s, 3H), 3.87 (s, 3H), 5.53 (s, 1H), 6.41 (d, J = 12.3 Hz, 1H), 6.47 (d, J 
= 12.3 Hz, 1H), 6.53 (s, 2H), 6.73 (d, J = 8.5 Hz, 1H), 6.80 (dd, J = 2.0, 2.0 Hz, 
1H), 6.92 (d, J = 2.0 Hz, 1H). HRMS-ESI (m/z): Calculated for C18H20O5 [M+ Na]+ 
: 339.1300; found: 339.1206 
2.6.2.2. Synthesis of compound 12: compound 12 was prepared according to 
the method described for compound 2 employing combretastatin A-4 (CA-4) (1 
eq.), potassium hydride (1.5 eq.), trichloroethylene ( 1.2 eq.) to give a white solid 
compound 12 (0.4g, 80 %).1H-NMR (300 MHz, CD2Cl2): 3.70 (s, 6H), 3.84 (s, 
3H), 3.87 (s, 3H), 5.53 (s, 1H), 6.41 (d, J = 12.3 Hz, 1H), 6.47 (d, J = 12.3 Hz, 
1H), 6.53 (s, 2H), 6.73 (d, J = 8.5 Hz, 1H), 6.80 (dd, J = 2.0, 2.0 Hz, 1H), 6.92 (d, 
J = 2.0 Hz, 1H). 
2.6.2.3. Synthesis of compound 13: Compound 13 was prepared according to 
the method described for compound 3 employing compound 12 (150 mg, 0.37 
mmol), 1.60 M n-BuLi (2.28 mL, 3.65 mmol), TMEDA (1.08 mL, 3.65 mmol) in 6 
mL of dry Et2O to afford 13 as orange brown solid (86.70 mg, 60%). 1H-NMR 
(300 MHz, CDCl3): 3.02 (s. 1H), 3.70 (s, 6H), 3.84 (s, 3H), 3.87 (s, 3H), 5.53 (s, 
1H), 6.41 (d, J = 12.3 Hz, 1H), 6.47 (d, J = 12.3 Hz, 1H), 6.53 (s, 2H), 6.73 (d, J = 






2.6.2.4. Synthesis of compound 14: Compound 14 was prepared according to 
the method described for compound 4 by employing compound 13 (80 mg, 0.23 
mmol), Cp2ZrCl2 (128.97 mg, 0.42 mmol), LiEt3BH (0.42 mL, 0.42mmol) and 
Iodine (I2) (132.82 mg, 1.05 mmol) to obtain 14 as white crystals. 
2.6.2.5. of compound 15: Compound 15 was synthesized and characterized as 
reported in literature.184 
 
2.6.3 Results and discussion 
Synthesis of the intermediates for the conjugates was successful until the final 
step. In the coupling reaction we followed the method described for compounds 
6. Separation of the final conjugate was performed using the preparative TLC but 
the NMR of the final compound could not be obtained as it decomposed 
spontaneously within the NMR tube. The result could be interpreted as such; 
CMP has a very high singlet oxygen quantum yield, hence, minimum amount of 
light could excite it. Direct conjugation of the electron-rich (vinyl diether) bond led 
to the generation of 1O2 at the vicinity of the bond with minimum light that cleaved 
the bond and was responsible with the observed instability of 16.  Therefore, the 









In summary, a facile and versatile synthetic scheme for E-1,2-diheteroatom-
substituted electron-rich alkenes was established for the first time. Not only 
symmetric vinyl diethers but also unsymmetrically heteroatom-substituted olefins 
could be prepared using phenols, thiols, and N-heterocycles with high 
stereospecificity. In addition to 1,2-diaryloxyalkene and 1-aryloxy-2-arylthio-
alkene, 1-aryloxy-2-amino-alkene also seems to react fast with singlet oxygen. 
Because we were faced with the challenge of the synthesis of the prodrug, using 
the vinyl diether linker, we resort to use the alternative linker (aminoacrylate 
linker) was developed which offer a number of advantages compared to the vinyl 
diether such as synthesis via easy and high yield reactions, stability, and 
regeneration of parent drug after cleavage. Moreover, the use of n-Buli in one of 
the steps limited the used of the scheme especially when the drugs were 










Chapter 3: DESIGN, SYNTHESIS AND CHARACTERIZATION OF FOLATE 
AND BIOTIN TARGETED PRODRUG DELIVERY SYSTEM OF PC-CA4  
3.1. Introduction 
Chemotherapy is often used to treat cancer, and it is expected to destroy the 
tumor cells for maximum treatment efficacy, while minimizing the side effects to 
other organs.185 However, conventional anticancer agents often have such a 
poor distribution, normal tissue damage and lack of target specificity. The 
development of tumor targeting drug delivery systems, able to selectively 
transport cytotoxic agents into the tumor site by exploiting subtle morphological 
and physiological differences between healthy and malignant cells, currently 
stands as one of the attractive strategies to overcome the selectivity problems of 
conventional chemotherapy. Active investigation in cancer treatment is being 
carried out on new targeted chemotherapeutic drugs that can report on the 
localization and activation of the drug upon selective internalization.186-188 As 
mentioned in the introduction, to actively target the drug delivery system or 
carrier, chemical modification by tumor targeting ligands is popular, e.g., biotin, 
antibody91, transferrin, folic acid epidermal growth factor and RGD peptide, 






Folic acid (FA) is a prominent ligand capable of specific interaction with cells 
expressing the folate receptor (FR). The folate receptor is a well-known tumor–
associated receptor that is overexpressed in many tumors, including those of the 
breast, lung, kidney, and brain and has little expression in normal tissues.187,190-
192 The overexpression of FR provides tumor cells with increased amounts of FA 
essential for DNA synthesis and seems to aid in aggressive tumor growth. 
Seminar observation of cancer patients overexpressing folate isoform α (FR-α) is 
that it tends to correlates with higher histological grade and more advanced stage 
of this disease.105 Therefore, FR can serve as both as a marker and target 
molecule for diagnosis and therapy of cancer.187 Various folate – drug conjugates 
such as folate conjugated to cytotoxic drugs e.g., camptothecin,193 taxol,194 
mitomycin C,195-197 and folate tethered protein toxins such as momordin198 and 
Pseudomonas exotoxins,199 etc. have been developed and tested in culture cells, 
animal models, and in human clinical trials with successful results as stated in 
the introduction. The drugs are conjugated through cleavable linker that 
constitute prodrugs that are released upon cell internalization but none of these 
conjugates possesses both activatable cytotoxicity and fluorescent imaging 
capabilities and intracellular localization upon cell entry.193-197 Although folate 
conjugates with florescent dyes and nanoparticles have been developed to 
determine the intracellular localization and presence of folate receptor, they lack 
therapeutic modality.200,201. Moreover, some of the folate conjugates such as; bis-
( haloethyl) phosphoramidites,202 PEG carboplatin,203 10–mer a conjugate of 






(FdUMP),204 and paclitaxel,205 although synthesized, were of limited success 
(lower potencies)206 probably due to lack of active release mechanisms within the 
conjugates. Hence, there is need for multimodal folate targeting drug delivery 
system which can actively target the cancer cells, release the payload, image 
and carryout therapeutic functions. 
Biotin (vitamin B7, vitamin H, Figure 12) is an essential micronutrient for normal 
cellular function growth and development.207 Biotin is involved in two ways in 
targeted cancer therapy. 1) In rapidly dividing cancer cell lines, biotin uptake is 
greater than that seen in normal tissues.208 Biotin receptors are over expressed 
more than FA receptors on several cancer cell lines, including leukemia 
(L1210FR), lung (M109), renal (RENCA, RD0995) and breast cancer cells (4T1, 
JC, MMT06056).209Although the structure(s) of the biotin receptor is /are not 
known,209,210 it has been suggested that the sodium-dependent multivitamin 
transporter is involved in biotin uptake.211,212 Cells that overexpressed biotin 
receptors are known to be targeted by the biotin conjugates via endocytosis.213 
(ii) Biotin has the highest affinity to two proteins avidin and streptavidin with a 
dissociation constant of 10-15.214 We will not focus on this biotin streptavidin drug 
targeting methodology but rather we will focus on the targeting of active species 
by conjugation to biotin via their receptors. Since its research has indicated that 
cancer cell lines that overexpress folate receptors, most of time equally show the 
overexpression of the biotin receptors,209 it stands to reason that developing a 






possible since not much clinical work has been done that far on this newly 
discovered receptor and can possibly be a substitute for the folate or serve as a 
dual targeting ligand together with the folate in the same construct. 
‘ 
 
Figure 12. Structure of Biotin 
As I said in the introduction, PDT is a promising new therapeutic tool for the 
management of a variety of solid tumors. It involves the administration of a 
nontoxic photosensitizer a drug, followed by activation of the drug with light of 
specific wavelength (600-800 nm). PDT generates singlet oxygen and other 
reactive oxygen species (ROS) that cause an oxidative stress and membrane 
damage in the treated cells and eventually cell death. The selectivity of PDT is a 
result of a low-to-moderate degree of selective photosensitizer uptake caused by 
proliferating malignant lesion followed by the focused illumination of tumor with 
red or NIR that is able to penetrate the tissue. The conventional PDT has been 
less commonly used for cancer therapy because the current non-targeted 






including skin photosensitization.10,62,218 Various methods used in targeting 
chemotherapeutic agents have also been used to target the photosensitizers. 
Various combinations of conventional photosensitizers and monoclonal 
antibodies (mAbs) have been tested to improve their selectivity with limited 
success, especially when measured by in vivo therapeutic effects.219-223 
Polymeric carriers including polymer–photosensitizer conjugates,224,225 PS-
loaded nanocarriers, long circulating liposomes226 and polymeric micelles,227-230 
have also been developed to passively target the tumor via enhanced 
permeability and retention (EPR) effect.231 PSs have also been conjugated to 
peptides, 232as well as other small ligands such as folic acid 233,234 for site-specific 
targeting photosensitizers to tumor tissues. Each of this targeting methodology 
has always been encountered with other challenges at the animal models. 
Hence, there is need to design specifically targeted photosensitizers in order to 
enhance phototoxicity as a result of higher and more selective accumulation in 
tumor cells and reduction in skin phototoxicity of this therapy. 
3.2. Hypothesis 
We hypothesized that by conjugating prodrug to folic acid via a PEG spacer we 
could actively target the prodrug to the tumor tissue by exploiting the high affinity 
of the FA to the FR ultimately improving the photodynamic response and at the 
same time actively triggering the release of the CA-4 into the tumor mass while 







3.3. Experimental Design 
In this study we evaluated the ability of both folate and biotin targeted prodrugs to 
deliver the conjugates to the tumor by exploiting the overexpression of their 
receptors on the cancer cells as compared to the normal cells. Seven 
conjugates: FA-PC-CA4, PC-CA4, FA-PEG2-PC-CA4, Boc-PEG897-PC-CA4, 
FA-PEG897-PC-CA4, Biotin-PEG897-PC-CA4 and FA-PEG2K-PC-CA4 were 
designed and synthesized. They were synthesized by conjugating PC-CA4 
(generated click reaction of 17 to 16) to FA directly or PEGylated folic acid or 
biotin of variable lengths as seen in the synthetic schemes below. To evaluate 
the efficiency of the conjugates as photosensitizers, some of the photophysical 
properties of all the six conjugates and the in vitro photodynamic activities of 
three lead conjugates selected from in vivo imaging screening were studied. 
Photophysical studies: the UV/Visible absorption spectra, molar extinction 
coefficients and the aggregation tendency were studied. 
In vitro studies of dark toxicity, phototoxicity, cellular uptake, competition assays, 
and sub-cellular localization of selected conjugates were evaluated using colon 






In vivo optical screening: The rate of uptake and receptor targeting capabilities of 
the conjugates were evaluated in vivo in balb/c mice bearing colon 26 cancer cell 
lines and leads were then selected for further studies. 
These conjugates were designed and synthesized combining the two basic 
principles that may be necessary to fulfill “Paul Ehrlich’s” vision of “magic bullet” 
for the treatment of diseases. 1) Site-specific delivery by targeting either the FR 
or biotin receptors in the tumor to direct the drug (CA-4) away from normal 
tissues that is particularly sensitive to the toxic action of the carried payload. 2) 
Site-specific triggering mechanism which by incorporating the photocleavable 
aminoacrylate linker could increase the release and therapeutic efficiency of the 
carried drug dramatically (this concept has been proven by Dr. Bio Moses in our 
lab).158 The combination of these two principles could lead to high local drug 
bioavailability specifically in tumor tissue while maintaining the stability of the 
drug delivery system in circulation. Furthermore, in designing the folate 
conjugates other useful criteria for producing active lead compounds were also 
taken.  








Figure 13. Schematic design of multifunctional prodrug. 
- Use of highly potent drug (module 5):  Since there is finite number of FR per cell 
and the folate recycling rate is 8-12 h, there will be a saturable period of 
exposure to the CA-4 and under these conditions CA-4 with its intrinsic IC50 
value in the low µM range will produce the required cytotoxic effects. 
- Enhanced hydrophilicity: The PC-CA4 prodrug is highly lipophilic and can 
passively diffuse through the cell membrane bilayer. By PEGylation or 
introducing a hydrophilic spacer (module 2) between the FA (module 1) and PC 
(module 3)  we hope not only to increase the biocompatibility of the prodrug but 
to also enhance the hydrophilicity, thereby forcing the greasy prodrug to 
exclusively enter the FR positive cells via FR-mediated endocytosis rather than 
indiscriminate diffusion into the cells. The spacers used by other groups for this 
purpose are peptides 195,235-239 or carbohydrates.235,240-242 By using PEGs of 






ensure the hydrophility of our prodrug but also easy targetability of FR on tumor 
tissue in vivo. 
- Choice of photosensitizer. We choose silicon dichloride phthalocyanine 
because it could easily be functionalized at the axial position, let alone the fact 
that most metallated phthalocyanines are used clinically as PDT and imaging 
agents. Therefore using the two axial positions available in pc-4 we could 
asymmetrically functionalized them with homing device and the drug- linker. In 
this study, we developed a folate base photosensitizer that is activated by NIR 
light for theranostic purpose when uptaken by the cancer cells. Further, because 
this agent also emits fluorescence, it can also be used to direct the application of 
light to minimize exposure to non-relevant tissues and to noninvasively monitor 
any therapeutic effects of excitation light. 
- Low molecular weight: By limiting the average size of our conjugates well below 
4000Da we anticipate that they will allow for better penetration into the solid 





















3.4 Experimental Procedure 
3.4.1. General Method 
All solvents and reagents used were obtained from Sigma-Aldrich, Alfa Aesar, 
Thermo Fisher Scientific, Polypure Inc., and Nanocs Technology Inc. unless 
otherwise stated. All reactions were monitored by TLC using 5-17 µm silica gel 
plates with fluorescent indicators from Sigma Aldrich (catalog # Z193291-1PAK). 
All chromatography was performed using 32-63 µm silica gel Sorbent 
Technologies (Catalog # 02826-26). All preparative TLC separations were 
performed using silica gel GF preparative layer uniplate chromatography plates 
with UV254 prep-scored 20 X 20 microns from Analtech Inc. (Catalog # 02003) 
All dialysis were performed using 7 Spectra/Por dialysis membrane (MWCO: 
1000 DA) from Spectrum Laboratories, Inc. NMR solvents with residual solvent 
signals were used as internal standards and NMR spectra were recorded using a 
Mercury 300 MHz spectrometer. 














Scheme 4. General synthetic scheme for the conjugates. A) Silicon 
phthalocyanine dichloride (1), (1.15 mmol), 1-(2- Hydroxyethyl)piperazine (10.30 
mmol), Reflux, Toluene/Pyridine ( 70 mL/1.75 mL) overnight, 80% yield. B) 17 
(0.47 mmol), 16 (0.47 mmol), in THF (150 mL) at rt for 1 h, 60% yield. C) i) 19 
(0.034 mmol) DCC (0.21 mmol) DMF/Pyridine (5:1 v/v), Sonicate, 30 min, ii) add 
18 (0.034 mmol) at rt, 24 h, iii) precipitate, Et2O/Acetone (3:1 v/v), iv) Dialysis, 48 
h, 60% yield. D) 18 (0.086 mmol), 5-Hexynoic acid (0.17 mmol), HBTU (0.17 
mmol), DIPEA (0.34 mmol), DCM (4 mL) at rt, 1 h, 80% yield. E) 18 (0.072 
mmol), Digycolic anhydride (0.072 mmol) at rt, DMF (6 mL), 36 h, 70% yield. F) i)  
22 (0.033 mmol), N3CH2CH2PEG2FA (26) (0.033 mmol), CuBr (0.033 mmol), 
PMDETA (0.033 mmol) at 37 oC, DMF (2 mL), 48 h, ii) Dialysis, 72 h, 60% yield. 
G) 23 (0.033 mmol), NH2CH2CH2PEG2KFA (28) (0.033 mmol), HBTU (0.050 
mmol), DIPEA (0.099 mmol) at rt DMF (4 mL) overnight, 70%. 







Scheme 5. Synthesis of compound 17: A) 9 eq 1-(2-Hydroxyethyl)piperazine , 
toluene/pyridine (5:1 v/v), reflux 8 h 
A mixture of silicon (IV) Phthalocyanine dichloride (0.7 g, 1.15 mmol), 1-(2-
Hydroxyethyl) piperazine (1.34 g, 10.30 mmol), and pyridine (1.75 mL) in toluene 
(70 mL) was refluxed overnight. After evaporation of the solvent at reduced 
pressure using the rotavap, the residue was then dissolved in DCM (300 mL) and 
then washed with water (400 mL x 4). The organic layer was collected and 
evaporated to dryness and the crude product recrystallized from DCM/ Hexane 
(1:9 v/v) to give a deep solid product (0.74 g, 80% yield).243 
1H-NMR (300 MHz, CD2Cl2): -1.19 (t, J = 5.8 Hz, 4H), -0.82 (t, J = 5.8 Hz, 4H), 
0.29 (m, 8H), 1.75 (m, 8H), 8.30 - 8.40 (m, 8H, Pc-H), 9.55-9.69 (m, 8H, Pc-H), 
MS-ESI (m/z): Calculated for C46H49N12O2Si [M+H]+ 828.38 Found: 828.37 







Scheme 6. Synthesis of compound 18: B) 17 (0.47 mmol), 16 (0.47 mmol), in 
THF (150 mL) at rt, 1 h, 60% yield. 
To a 150 mL dry THF solution in a round-bottom flask equipped with a magnetic 
stirring bar was added 17 (0.38 g, 0.47 mmol). The solution was purged and 
maintained for 10 min in N2 atmosphere.  CA-alkyne (16) (0.17 g, 0.47 mmol) 
dissolved in 30 mL dry THF was then added drop-wise into a vigorously stirring 
solution of 17 for over 1.5 h and then allowed to stir for further 15 min. The 
reaction mixture was then evaporated under reduced pressure and the crude 
product was purified using either the preparative TLC or a short column 
chromatography first using the solvent system ethylacetate/methanol (4:1 v/v) to 
remove the di-substituted product, followed by DCM/MeOH/NH4OH (79:17: 4 % 
v/v/v) to afford the target compound 18 as a blue solid (0.32 g, 60%). This 
compound then served as an intermediate for all the conjugates.244 
1H-NMR (300 MHz, CD2Cl2-d2): 9.67 (br s, m, 8H), 8.38 (br s, 8H), 7.19 (d, J = 
11.9 Hz, 1H), 7.00 (m, 2H), 6.85 (d, J = 11.9 Hz, 1H), 6.52 (s, 2H), 6.46 (m, 2H), 
4.35 (d, J = 12.99 Hz, 1H) 3.76 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.65 (s, 6H, 
OMe), 2,19 (br s, 8H), 1.65 (br s, 1H, NH), 0.29 ( br s, 8H), -0.37 ( m, 4H), -1.94 
(m, 4H). HRMS-ESI: Calcd for C84H79N19O13Si: m/z 1166.4583; [M+H]+, 














Scheme 7. Synthesis of compound 21: C) i) 19 (0.034 mmol) DCC (0.21 mmol) 
DMF/Pyridine (5:1 v/v), Sonicate, 30 min, ii) add 18 (0.034 mmol) at rt, 24 h, iii) 
precipitate, Et2O/Acetone (4:1 v/v), iv) Dialysis, 48 h, 60%. 
To a stirring solution of folic acid (0.015 g, 0.034 mmol) in anhydrous 
DMF/pyridine (5:1 v/v) solution, DCC (0.043 g, 0.21 mmol) was added in one 
portion. The reaction mixture was kept in an ultrasound bath in the dark for 30 
min. Then the resulting suspension was quickly filtered over a sintered funnel 
and the precipitate was washed with minimum amount of DMF/pyridine 
solution.245 Solution of 18 (0.040 g, 0.034 mmol) was added into the filtrate. The 
resulting mixture was further stirred at room temperature in the dark for 24 h. The 
crude reaction mixture was then purified either by passed through gel permeation 
G-15 Sephadex column, using DMF as the eluent to separate the product from 
the unreacted folic acid starting material. The top stop was then collected and 
poured drop-wise into a stirred solution of cold Et2O/ acetone (4:1 v/v) to afford a 
green precipitate that was collected over a sintered glass funnel. An alternative 
method wash by simply precipitating in cold Et2O/ acetone (4:1 v/v) then followed 
by dialysis in DMF with cellulose membrane of MWCO of 1000 Da for 48 h. After 
washing several times with cold acetone and Et2O the material was dried to give 
a deep blue solid product (33.5 mg, 60%) with more than 90% purity. See SI for 
the HPLC chromatogram. 
1H-NMR (300 MHz, DMSO-d6): 9.67 (br s, 9H), 8.65 (s, 1H), 8.49 (m, 8H), 7.64 






6.48 (m, 2H), 4.49 (br s, 2H), 4.30 (d, J = 11.43 Hz), 4.17 (m, 1H), 3.71 (s, OCH3, 
3H), 3.61 (s, 3OCH3, 9H), 2.35 (m, 2H), 2.20 (br s, 8H), 1.21 (br s 2H), 0.22-
0.12(0.18) (m, 8H), -0.7 (m, 4H). 13C-NMR (75 MHz, DMSO-d6): 166.64, 152.98, 
152.98, 151.33, 149.25, 140.37, 135.42, 132.57, 132.41, 129.02, 124.03, 112.86, 
106.39, 60.48, 56.11, 56.06, 31.16. MS-ESI: Calcd for C84H79N19O13Si: m/z 
1589.59; [M+H]+, 1590.60; [M+H]+2, 795.30. Found: [M+H]+, 1590.59; [M+H]+2, 
795.30 
3.4.2.4. Synthesis of 22 
 
Scheme 8. Synthesis of compound 22: 18 (0.085 mmol), 5-Hexynoic acid (0.17 






To a 5 mL dry DCM stirring solution of 18 (0.10 g, 0.085 mmol), was added 5-
hexynoic acid (0.019 g, 0.17 mmol) and N,N-diisopropylethylamine (DIEA) (56.6 
µL, 0.044 g, 0.34 mmol) and O-(benzotriazol-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate (HBTU) (0.065 g, 0.17 mmol). The reaction mixture was left 
for 2 h at room temperature and monitored using the TLC.  At the end of the 
reaction, the reaction mixture was diluted with 60 mL of DCM and washed with 
water (200 ml x 3 times). The organic filtrate was then dried using anhydrous 
sodium sulfate (Na2SO4) and evaporated to dryness in vacuo. The crude was re-
dissolved in minimum DCM, and the recrystallized using a mixture of cold 
hexane/ Et2O. The solid residue was washed several times with diethyl ether to 
afford a deep blue solid product (87 mg, 80%). 
1H-NMR (300 MHz, CD2Cl2-d2): 9.67 (br s, m, 8H), 8.38 (br s, 8H), 7.19 (d, J = 
11.9 Hz, 1H), 7.00 (m, 2H), 6.85 (d, J = 11.9 Hz, 1H), 6.52 (s, 2H), 6.46 (m, 2H), 
4.35 (d, J = 12.99 Hz, 1H) 3.76 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.65 (s, 6H, 
OMe), 2.51 (s, 1H) 2,19 (br s, 8H), 1.95(m, 2H), 1.56 (m, 4H), 0.29 ( br s, 8H), -
0.37 ( m, 4H), -1.94 (m, 4H). HRMS-ESI: Calcd for:  C71H68N12O9Si m/z 
1260.5001; [M+Na]+,1283.4899; Found [M+Na]+,1283.4879. 







Scheme 9. Synthesis of compound 23: E) 18 (0.072 mmol), Digycolic anhydride 
(0.072 mmol) at rt, DMF (6 mL), 36 h, 70%. 
To a 6 mL anhydrous DMF in 10 mL round bottomed flask equipped with 
magnetic stir bar was added 18 (0.084 g, 0.072 mmol), and diglycolic anhydride 
(0.0084 g, 0.072 mmol) at room temperature and allowed to run for 36 h. The 
reaction mixture was poured drop-wise into cold Et2O and the blue precipitate 
was filtered using a sintered glass funnel. This was further washed with more 
diethyl ether solvent to obtain a blue solid (64 mg, 70 %). 
1H-NMR (300 MHz, CD2Cl2): 9.67 (br s, m, 8H), 8.38 (br s, 8H), 7.19 (d, J = 11.9 
Hz, 1H), 7.00 (m, 2H), 6.85 (d, J = 11.9 Hz, 1H), 6.52 (s, 2H), 6.46 (m, 2H), 4.35 
(d, J = 12.99 Hz, 1H), 3.98 (s, 2H), 3.91 (s, 2H) 3.76 (s, 3H, OMe), 3.70 (s, 3H, 






1.94 (m, 4H). HRMS-ESI: Calcd for C69H67N12O12Si, m/z 1282.4692; [M+H]+, 
1283.48. Found [M+H]+ 1283.4761. 
3.4.2.6. Synthesis of FA-PEG2-PC-CA4 (27) 
Folate-PEG2-N3 [N3CH2CH2PEG2FA, (26)] (0.020 g, 0.033 mmol) and 22 (0.042 
g, 0.033 mmol) were dissolved in 1.5 mL anhydrous DMF. After purging with 
nitrogen gas at room temperature, N,N,N′,N′′,N′′-pentamethyldiethylenetriamine 
(PMDETA) (0.0058 g, 0.033 mmol, 7 µL) and CuBr (0.0048g, 0.033 mmol) were 
added and the solution stirred at 37 oC for 48 h. The reaction was stopped by 
opening to air and mixture diluted with DMF. It was then washed with water to 
eliminate copper and the crude extensively dialyzed against DMSO for 72 h 
(cutoff MW 1000) and then precipitated using cold Et2O / acetone mixture (4:1 
v/v) to afford 27 as green precipitate, 60%. 
HRMS-ESI: Calcd for [C96H120N123O16SiNa]+2; [M+H2O+Na+H]+2, 951.45 (100 %); 







Scheme 10. Synthesis of compound 27. 22 (0.033 mmol), N3CH2CH2PEG2FA 
(26) (0.033 mmol), CuBr (0.033 mmol), PMDETA (0.033 mmol) at 37 oC, DMF (2 
mL), 48 h, ii) Dialysis, 72 h, 60%.    






Following the same method described for the synthesis of compound 21 (PC-
CA4), compound 25 (217 mg, 1.25 mmol), FA (19) (500 mg, 1.13 mmol), DCC 
(1440 mg, 6.99 mmol) and 48 mL toluene/pyridine (5:1 v/v) were employed to 
obtain compound 26 as yellow solid (450 mg, 65 %).245 
 
Scheme 11. Synthesis of compound 28. A) Triethylene glycol (25.7 mmol), 
methanesulfonyl chloride (51.50 mmol) TEA (51.50 mmol) in 10 mL THF reflux at 120 
oC. B) 24 (15.40 mmol), 0.65M H3PO4 (40 mL), PPh3 (15.20 mmol, 30 mL), C) i) 19 






25 (0.034 mmol) at rt, 24 h, iii) precipitate, Et2O/Acetone (4:1 v/v), iv) Dialysis, 48 
h, 60%. 
3.4.2.8. Synthesis of compound 24 
To 40 mL of dry THF under N2 was added triethylene glycol (3859.37 mg, 24.7 
mmol). methanesulfonyl chloride (4.01 mL, 51.50 mmol) was added by syringe, 
and the solution was stirred in an ice bath as TEA (7.24 mL, 51.50 mmol) in 10 
mL of THF was added for 30 min. The ice bath was removed after 1 h of stirring, 
and the mixture stirred for an additional 5 h with occasional swirling. The yellow-
white precipitate was dissolved by addition of H2O (24.40 mL), and the resulting 
two phases were chilled on a cold water bath. NaHCO3 (2.50 g, to pH 8) was 
added followed by NaN3 (3.35 g, 51.50 mmol), and stirring was commenced. 
Then, THF was removed by distillation, and the solution was refluxed for 48 h at 
a temperature of 120 oC. The aqueous layer was extracted five times with 20 mL 
aliquots of Et2O, with each layer of Et2O back-extracted with the same 20 mL 
aliquot of brine (saturated NaCl). The organic layers were then combined, dried 
over anhydrous Na2SO4 and filtered. Concentration of the organic layers by 
rotary evaporation yielded 24 as a yellow oil (4.40 g, 80 %) .246 
 1H-NMR (300 MHz, CDCl3): 3.61 (m, 8H), 3.32 (m, 4H). MS-ESI: Calcd for 
C6H12N6O2: m/z 200.10; [M+H]+, 201.11. Found; [M+H]+, 201.12 






Aqueous H3PO4 (40 mL of 0.65 M) was added to the diazide 24 (2894.53 mg, 
15.4 mmol) and the solution was brought to stirring with PPh3 (3390 mg, 15.20 
mmol) in 30 mL of Et2O was added drop-wise over 1 h. The addition funnel was 
then rinsed with 10 mL of ether, and the solution was placed under N2 and stirred 
for 24 h. The aqueous layer was separated and washed with 4 x 30 mL of Et2O 
and 3.20 g of KOH was added. The mixture was cooled to 4 oC after removal of 
traces of ether by evaporation. After 16 h, the PPh3 was removed by filtration 
followed by addition of 9.20 g of KOH (to 4.0 M). The aqueous solution was then 
extracted several times with 20 mL aliquots of DCM, which were then dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford 
25 as a brownish oil (1.07 g, 70 %)  .246 
1H-NMR (300 MHz, CDCl3): 3.63 (m, 6H), 3.51 (m, 2H), 3.32 (m, 2H), 2.83 (m, 
2H), 2.0 (br s 2H, NH2). MS-ESI: Calcd for C6H14N4O2: m/z 174.11; [M+H]+, 
175.12. Found; [M+H]+, 175.12. 







Scheme 12. Synthetic scheme for compound 29: G) 23 (0.033 mmol), 
NH2CH2CH2PEGnFA (28) (0.033 mmol), HBTU (0.050 mmol), DIEA (0.099 







To a 4 mL anhydrous DMF in a 10 mL round-bottom flask equipped with a 
magnetic stir bar was added FA-PEGn-CH2CH2NH2 (28) (0.078 g, 0.033 mmol), 
23 (0.044 g, 0.034 mmol), DIEA (0.099 mmol), and HBTU (0.019 g, 0.050 mmol) 
at room temperature and allowed to stir for 3 h. The crude reaction mixture was 
passed through a G-15 Sephadex column using DMF as the eluent. With the 
molecular weight of the final product greater than 1500 g/mol, the products 
passed through the void volume and were collected as the fast moving spot from 
the solvent front. The product was dialyzed for 48 h against DMF and 
subsequently DCM for 12 h to get rid of the DMF. (MWCO 1000 Da). The 
Product in DCM was concentrated in vacuo and precipitated into 71 mg sticky 
dark green solid product using cold Et2O.  1H-NMR (300 MHz, DMSO-d6) (Figure 
63): 9.67 (m, 9H, 1’, 4’, 20), 8.40 (m, 8H, 2’,3’), 7.96 ( br s, DMF peak), 7.69 (m, 
1H), 7.41 (m, 2H, 14, 17), 7.10 d, J = 11.9 Hz, 1H, 5), 7.00 (m, 2H, 9, 7), 6.85 (m, 
2H, 6, 13), 6.52 (br s, 4H, 15,16,1,2), 6.46 (m, 1H, 12), 4.35 (d, J = 12.99 Hz, 1H, 
8), 4.24 (m, 1H, 12), 3.85 (br s, 2H,  g, m), 3.78 (s, 4H, e, f), 3.73 (s, OMe, 3H), 
3.68 (s, 3xOMe, 9H), 3.58 ( br s, complex, j, t, h), 2.91 (s, DMF), 2.82 (s, DMF), 
2.21 (m, 8H, c), 1,67 ( br s, H2O), 0.31 (m, 8H, d, d’), -0.58 (m, 4H, b), -1.90 (br s, 
4H, a) 







Scheme 13. Synthesis for compound 34 and 35. A) 30 (0.56 mmol), Boc2O (0.56 
mmol) TEA (1.67 mmol), anhydrous MeOH (9.31 mL), reflux, 24 h. B) sonicated 
FA, (0.19 mmol) in DCC (1.13 mmol), 30 min, DMF/Pyridine (5:1 v/v), 31 (0.19 






(0.23 mmol), HBTU (0.23 mmol), DIEA (0.23 mmol), anhydrous DMF (4 mL) at rt 
, 3 h. D) TFA at rt, 4 h. 
3.4.2.12. Synthesis of mono-protected diamine (31)  
 
Scheme 14. Synthesis of compound 31:  30 (0.56 mmol), Boc2O (0.56 mmol), 
TEA (1.67 mmol), reflux, anhydrous MeOH (9.31 mL), 24 h, 75%. 
A stirring solution of PEG-diamine (30) (500 mg, 0.56 mmol) in anhydrous MeOH 
(9.31 mL) was treated with Boc2O (122.50 mg, 0.56 mmol) and TEA (177.60 µL, 
1.67 mmol). The reaction mixture was left at reflux for 24 h. The solvent was 
removed under reduced pressure and the resulting yellow oil was purified by 
silica gel chromatography using DCM/MeOH/NH4OH (79:17:4 % v/v/v) as the 






1H-NMR (300 MHz, D2O-d2): 3.64 (br s, -CH2- of PEG), 3.20 (m, 4H), 3.00 (m, 
4H), 1.43 (s, 9H, t-butyl group). MS-ESI: Calcd for C45H92N2O21: m/z 996.62; 
[M+H]+, 997.63. Found; [M+H]+, 997.70. 
3.4.2.13. Synthesis of Boc-PEG 897-FA (32). 
 
Figure 16. Structure of compound 32 
To a stirring solution of FA (0.083 g, 0.19 mmol) in anhydrous DMF/pyridine (5:1 
v/v) solution, DCC (0.23 g, 1.13 mmol) was added in one portion. The reaction 
mixture was kept in an ultrasound bath in the dark for 30 min. Then the resulting 
suspension was quickly filtered over a sintered funnel and the precipitate was 
washed with minimum amount of DMF/pyridine solution. Mono-protected diamine 
(31) (180 mg, 0.19 mmol) was then added to the filtrate and allowed to stir in 






solution of cold Et2O/ acetone (4:1 v/v) to afford a yellow precipitate that was 
collected on a sintered glass funnel. After washing several times with cold 
acetone and Et2O the material was dried to give a deep yellow solid product 
which was further purified by passing over Sephadex G-15 using deionized water 
as a solvent to remove any unreacted folic acid (196 mg, 80 %).   
  1H-NMR (300 MHz, D2O-d2) [Figure 82]: 8.60 (s, 1H, 20), 7.52 (br s, 2H, 15, 16), 
6.62 (br s, 2H, 14, 17), 3.52 (br s, -CH2- of PEG block), 1.27 (s, 9H, t-butyl 
group). MS-ESI: Calcd for C64H109N9O26: m/z 1419.75; [M+H]+, 1420.76. Found; 
[M+H]+, 1420.70, [M+Na]+, 1442.70. 
3.4.2.14. Synthesis of Boc-PEG 897-Biotin (33) 
 
Figure 17. Structure of compound 33 
A mixture of D-(+)-Biotin, (54.88 mg, 0.23 mmol), compound 31, (214.10 mg, 
0.23 mmol), HBTU (85.22 mg, 0.23 mmol) and DIEA (37 µL, 0.45 mmol) in 3 mL 






and the residue was purified by silica gel column chromatography using DCM 
/MeOH as eluent (9:1 v/v) to give a gray colored solid (84 %). 
  1H-NMR (300 MHz, CDCl3) [Figure 83]: 7.79 (d, J = 8 Hz, 1H), 7.60 (d, J = 8.2 
Hz, 1H), 7.38- 7.25 (m, 1H), 7.00 (m, 1H), 4.46 (m, 1H) 4.30-4.20 (m, 1H), 3.59-
3.49 (complex, PEG, H), 2.24 (m, 2H), 1.71-1.51 (m, 5H), 1.42 (br s, 9H). MS-
ESI: Calcd for C64H109N9O26: m/z 1419.75; [M+H]+, 1420.76. Found; [M+H]+, 
1420.70, [M+Na]+, 1442.70 
3.4.2.15. Synthesis of H2N-PEG 897-FA (34) and H2N-PEG 897-Biotin (35) 
 
Figure 18. Structures of compound s 34 and 35 
Boc deprotection on both compound 32 and 33 were accomplished using TFA at 
room temperature and the deprotected products used for the next respective 
steps without further purification.  







Figure 19. Structure of compound 36 
The procedure for this synthesis was similar to that of compound 29.  Compound 
34 (0.082 g, 0.062 mmol), compound 23 (0.080 g, 0.062 mmol), HBTU (0.026 g, 
0.069 mmol) and DIEA (22.80 µL, 0.14 mmol) in 4 mL anhydrous DMF afforded a 
dark green solid product after similar purification process (100.90 mg, 70 %). 
1H-NMR (300 MHz, CD2Cl2-d2 ) [Figure 73]: 9.67 (m, 8H, 1’, 4’, 2), 8.40 (m, 8H, 
2’,3’), 7.69 (m, 1H), 7.41 (m, 2H, 14, 17), 7.10 d, J = 11.9 Hz, 1H, 5), 7.00 (m, 
2H, 9, 7), 6.85 (m, 2H, 6, ), 6.52 (br s, 2H, 15, 1,2),  12), 4.35 (d, J = 12.99 Hz, 
1H, 8), 3.85 (br s, 2H,  g, m), 3.78 (s, 4H, e, f), 3.73 (s, OMe, 3H), 3.68 (s, 
3xOMe, 9H), 3.58 (br s, complex, j, t, h), 2.21 (m, 8H, c), 1,67 (br s, 9H, 10), 0.31 






3.4.2.17. Synthesis of Biotin-PEG897-PC-CA4 (37) 
 
Figure 20. Structure of compound 37 
The procedure was similar to that of compound 29. H2N-PEG 897-Biotin (35) (48 
mg, 0.043 mmol), compound 23 (55.42 mg, 0.043 mmol), HBTU (18.02 mg, 
0.047 mmol) and DIEA (16 µL, 0.095 mmol) in 4 mL of anhydrous DMF stirring  
at room temperature  for 4 h gave  dark green solid (51.25 mg, 60 %).  
1H-NMR (300 MHz, CD2Cl2-d2) [Figure 148]: 9.64 (m, 9H, 1’, 4’, ), 8.38 (m, 8H, 
2’,3’), 7.69 (m, 1H), 7.41 (m, 2H, 14, 17), 7.09 (d, J = 11.9 Hz, 1H, 5), 6.94 (m, 
2H, 9, 7), 6.83 (m, 1H, 6, ), 6.50 (br s, 2H, 1,2), 6.43 (m, 2H, 3, 4), 4.44 (m, 1H, 






2H,  f), 3.76 (s, 3H, OMe, 3H), 3.70 (s, OMe, 3H), 3.65 (s, 2 x OMe, 6H)  3.58 ( br 
s, complex, j, t, h), 2.19 (m, 10H, c, 10), 1.59 (m, alkyl chain), 1.22 (from PEG 
chain), , 0..29 (m, 8H, d, d’), -0..37(m, 4H, b), -1.93(br s, 4H, a). MS-ESI: Calcd 
for C119H162N16O32SSi: m/z 2388.83; [M+H]+, 2389.11. Found; [M+H]+, 2389.20. 
3.4.2.18. Synthesis of Boc-PEG897-PC-CA4 (38) 
	  
Figure 21. Structure of compound 38 
This compound was synthesized as a control following the same procedure 
described for compound 29. Compound 23 (102 mg, 0.080 mmol), compound 31 
(75.73 mg, 0.078 mmol), HBTU (33.18 mg, 0.088 mmol) and DIEA (28 µL, 0.18 






1H-NMR (300 MHz, CD2Cl2-d2) [Figure 150]: 9.67 (m, 8H, 1’, 4’), 8.40 (m, 8H, 
2’,3’),  7.69 (m, 1H), 7.10 (d, J = 11.9 Hz, 1H, 5), 7.00 (m, 2H, 9, 7), 6.85 (m, 1H, 
6, ), 6.52 (br s, 2H,1,2), , 4.35 (d, J = 12.99 Hz, 1H, 8), 4.24 (m, 1H, 12), 3.85 (br 
s, 2H,  g, m), 3.78 (s, 4H, e, f), 3.73 (s, OMe, 3H), 3.68 (s, 3xOMe, 9H), 3.58 ( br 
s, complex, j, t, h), 2.21 (m, 8H, c), 1.46 ( br s, 9H, t-butyl), 0.31 (m, 8H, d, d’), -
0.58 (m, 4H, b), -1.90 (br s, 4H, a). MS-ESI: Calcd for C114H156N14O32: m/z 
2261.08; [M+Na]+, 2284.07. Found; [M+Na]+, 2284.02. 
3.5. Photophysical studies 
3.5.1. Aggregation tendencies 
Aggregation tendency involves an association of solute molecules that does not 
involve covalent bonding to give assemblies of individual units in solutions.247 
Being a critical problem in PDT, photosensitizers readily aggregate in aqueous 
media producing species with lower quantum yields of singlet oxygen generation 
and thus lower photodynamic activities.248 The energy absorbed by a 
photosensitizer upon irradiation is lost to other photosensitizer molecules in the 
aggregates by collisional quenching leading to reduced fluorescence and singlet 
oxygen generation. When the fluorescence of PS is monitored in an aqueous 
media compared to that in organic solvents, then the aggregation tendency in the 






To determine the aggregation tendency of the conjugates in aqueous media, the 
fluorescence emission was compared with that observed in organic solvents 
(where the samples exist in monomeric forms). All experiments were carried out 
in aqueous media; thus, a comparison of the decrease in fluorescence observed 
in media compared to that observed in DMSO was used to estimate the 
aggregation. Although the aggregation tendency of dyes generally increases with 
their concentrations, only one concentration was chosen to test the solubility in 
different solvents. 
2 mM stock solutions of the respective conjugates were prepared in DMSO and 
diluted to 1 mL of 10 uM concentrations with the distilled water and DMSO 
respectively. The solutions were left 1 h after which the fluorescence readings 
were taken at 605 nm excitation and 640-800 nm emission wavelengths. The 
change in the fluorescence of the conjugates in water compared to that in DMSO 
was used as a measure of the aggregation tendencies which indirectly translates 
to their solubility.  
 
3.6. In vitro studies 






In order to determine the cytotoxicity of the conjugates in the absence of light 
(dark toxicity), folated, biotinylated and non-targeted prodrugs were evaluated for 
cytotoxicity without illumination against the colon 26 cell line. A total 5-10 x 103 
cells in 190 µL of the complete medium per well were plated in a 96-well plate, 
followed by incubation for 24 h at 37 oC in 5 % CO2. 10 µL of respective dilute 
solutions of the conjugates (previously diluted from the 4 mM stock solution to 
the appropriate concentrations using complete media) was then added to 190 µL 
of complete media in each well to achieve final concentrations ranges (0.0001- 2 
µM) and the well plates incubated for 24 h. Then the medium was removed and 
cell monolayers washed with ice-cold PBS (190 µL) three times. Clear medium, 
with neither phenol red nor bovine growth serum, was then added to the wells 
and the well plates were kept in the dark for 1 h. The clear medium was removed 
after this time and 190 µL of the complete medium was added. The plates were 
then incubated for 3 days at 37 oC in 5 % CO2 after which the cell viability was 
determined by MTT assay. In brief, a volume of 10 µL of MTT at a concentration 
of 10 mg/mL was added to 190 µL of complete media in each well. After 4 h of 
incubation, MTT solutions were removed and formazan crystals formed were 
dissolved in 200 µL of DMSO and the absorbance was measured at 570 nm with 
background subtraction at 650 nm. The cell viability was then quantified by 
measuring the absorbance of the treated wells, compared to that of the untreated 
wells (controls). The controls in the assays involve tests done with cells not 






The IC50 value for each   was calculated using nonlinear regression curve in 
GraphPad Prism 5.03 software based on the Hill (sigmoid Emax) 
equation.184,250The logarithmic concentrations of the conjugates were plotted 
against the percentage viability of cells grown in the absence of conjugate 
prodrugs. 
% Cell Survival =   !!"#!"!!!"#!" !"#$%#&  !"##$
!!"#!"!!!"#!" !"#$%"&
X 100%    
3.6.2. Phototoxicity 
In order to determine the cytotoxicities of the folated, biotinylated and non-
targeted prodrugs upon light exposure (phototoxicity), colon 26 cells were 
seeded on a 96 well plates at densities of 5-10 x 103 cells/well. The same 
procedure and concentrations ranges were used as in the determination of the 
dark toxicity and after 24 h incubation; the medium was removed and rinsed 
twice with 0.9 % NaCl solution. Clear medium, without phenol red and bovine 
growth serum, was then added to the wells and well plates irradiated for 30 min. 
To ensure a uniform distribution or illumination of light, the well plate was placed 
on an orbital shaker (Lab-line, Barnstead International) and the well plate lid 
removed before exposing the wells for 30 min to a 5.6 mW/cm2 from a 690 nm 
diode source and then gently orbiting the well plate over the entire 30 min. After 
the 30 min irradiation, the clear medium was then removed, and 190 µL of 






37 oC in 5 % CO2 for 3 days after which the cytotoxicity was determine by MTT 
assay and expressed as a percentage of the controls to that of cells exposed to 
light and not treated with the conjugates.184 
 
3.6.3. Cell Uptake Experiments 
To determine the intracellular accumulations of the folated, biotinylated, PC-CA4 
and non-targeted PEGylated conjugates, colon 26 cells were seeded in 6 well 
plates at 5 x 104 cells/well in 1.5 mL complete medium and incubated at 37 oC in 
5 % CO2 for 24 h. The 4 mM stock solutions of the conjugates in DMSO were 
diluted to 100 µM with cremophor formulation mixture composed 
PBS/EtOH/Cremophor (18:1:1 v/v) before addition to the wells. 300 µL of the 
respective dilute solutions were then added to 1200 µl of complete media in each 
well to achieve a 20 µM final concentration of conjugate per well and the well 
plates incubated at various time points. After every time point of incubation, the 
medium was removed and the cell monolayer was rinsed twice with PBS. 120 uL 
of DMSO was then added to each well to solubilize the cells for 5 min after which 
an additional 280 µL of absolute EtOH was added to the DMSO solution already 
in the wells and the fluorescence from PC was read using the multi-well plate 
reader (Molecular Devices, SpectraMax M2 model) set at 605 nm excitation and 
640 – 800 nm emission wavelengths. The intracellular concentrations of the 






dissolving the stock solutions of the conjugates in DMSO/EtOH in the same ratio 
as used in the used in fluorescence uptake experiment to obtain dilute solutions. 
The results were expressed in concentrations (M). 
 
3.6.4. Competitive binding assay of conjugates with excess folic acid or 
excess biotin 
In order to demonstrate that FA and FA-conjugates and biotin and biotin 
conjugates compete for of receptors, we preincubated 5 x 104 colon 26 cells in 6 
well plates which are FR-alpha receptor positive as well as biotin receptor 
positive with 1 mM FA and 1 mM biotin respectively. After 1 h in this condition we 
added FA-PEG2K-PC-CA4 or Biotin-PEG 897-PC-CA4 (all at 20 µM). At the 
end of each incubation period, fluorescence emission was taken as indicated in 
the uptake experiment.  
Briefly, colon 26 cells were incubated at cell densities of 5 x 104 cells in complete 
medium in 6 well-plates at 37 oC in 5 % CO2 for 24 h. The 5 mM folic or biotin 
stock solutions were prepared by dissolving appropriate amounts of the 
respective compounds in 1 mL DMSO at 60 oC and later diluting them in 
deionized water to make a total volume of 10 mL. 200 µL of the solution was then 
added to 1000 µL of complete medium in the well plate and incubated for 1 h 






receptors available on cancer cell membranes. At various time points, 
fluorescence of wells with free FA or biotin is taken following the same protocol 
as in the uptake experiment and compared with wells without free FA or biotin at 
that same time point. The results are expressed as fluorescence units within a 
given volume of solvent. 
 
3.6.5. Estimation of cellular uptake of conjugates by confocal fluorescence 
microscopy 
To assess the specificity of the conjugates to the cancer cells, colon 26 cells 
were seeded at densities of 1x104 cells/well in 24 well-plates containing 12 mm 
diameter cover slides and was then incubated for 24 h. FA-PEG2K-PC-CA4 and 
Boc-PEG897-PC-CA4 conjugates were diluted to appropriate concentration and 
25 µl of each diluted solution then added to the well-plates to achieve 10 uM final 
concentrations per well. The cells were incubated for 1.5 h and then the media 
was removed and cell monolayer rinsed three times with the complete media. 
The cover slides were removed and then mounted on the glass slide. The 
fluorescence caused by the two conjugates (all excited at 633 nm, monitored at 
650-750 nm) was recorded using confocal scanning microscope and images 
were taken using a leica DMI4000B fluorescence microscope fitted with QI 






3.7. In vivo optical imaging 
All animal experiments were carried out in compliance with the Animal 
Management Rules of IACCUC and the guidelines for the Care and Use of 
Laboratory Animals of the University of Oklahoma Health Sciences Center. 
Three to 4-week old female balb/c mice (n=3) (approximately 20 g, Charles 
Rivers Laboratories Inc.) were used to monitor, the bio-distribution and the tumor 
targeting ability of the seven conjugates synthesized (viz; PC-CA4, FA-PC-CA4, 
FA-PEG2-PC-CA4, FA-PEG2K-PC-CA4, Boc-PEG897-PC-CA4, FA-PEG897-
PC-CA4 and Biotin-PEG897-PC-CA4). The mice were implanted sub-
cutaneously with 2 X 106 colon 26 cells in PBS (100 µL) on the lower back neck 
region and tumor growth was monitored with digital caliper for 10 days until when 
the tumor diameter reached 5-6 mm length. The mice were then anesthetized in 
acrylic chamber with 2.5 % isoflurane/air mixture followed by injection with 
cremophor solutions (consisting of PBS/EtOH/Cremophor, 18:1:1 v/v) of the 
conjugates (2 umol/kg, i.v.). Then the images were taken using the IVIS imaging 
system (Caliper Life Sciences), which consisted, of cryogenically cooled imaging 
system coupled to the data acquisition computer running Living Image software. 
Fluorescence images were taken at 0, 15 min, 1h, 3 h, 7 h, 9 h 24 h, 48 h, and 
72 h post injection. During the imaging process, five different exposure times 
were selected viz; 0.5 s, 1 s, 2 s, 3 s and 5 s. The excitation and emission 






mice were anesthetized and during the post processing, image counts were 
adjusted to 5 x103 as minimum and 3 x 104 a.u. as maximum color scale.252 
 
3.8. RESULTS AND DISCUSSION 
3.8.1. Synthesis 
We design the conjugates base on the following principles 1) Phthalocyanine is 
an effective imaging and therapeutic agent. 2) PEG is a biocompatible and stable 
linker that increases the hydrophilicity of the conjugate and is recommended by 
FDA for biomedical applications. 3) Folate and biotin are effective homing 
molecules targeting FR and biotin receptor expressing tumors respectively. 4) 
CA-4 is chemotherapeutic agent (antitubulin agent). On the basis of this design, 
we synthesized four folated and one biotinylated PC-CA4 prodrugs as seen in 
the scheme following very versatile methods and high yields as seen in the 
scheme above. 
3.8.2. Electronic absorption and photophysical properties 
The absorption spectra of six out of the seven conjugates are summarized in 
Table 4. The compounds gave absorption spectra that were typical 






676 and two other vibronic bands at 604-607 and 642-647 nm.243 The similarity in 
their Q- bands absorption indicates that the π-system of these compounds is not 
perturbed by the axial ligands. It is worth noting that λmax for both FA-PC-CA4 
and FA-PEG897-PC-CA4 are quite similar in almost all the wavelengths and a bit 
lower than those of the other conjugates. The explanation for FA-PC-CA4 may 
be due to the direct conjugation of FA (which is highly insoluble in most organic 
solvent except DMF and DMSO) to a highly lipophilic prodrug (PC-CA4) 
introduce some ampiphilicity to the molecule that may lead to π- π stack stacking 
and subsequent aggregation even in the organic solvent. But the introduction of 
PEG 897 which is shorter between FA and PC seems not to alleviate the 
situation hence a need for a longer PEG. There may be some other reason 
attached to that reduced extinction coefficient for this compound. We did expect 
similar results from FA-PEG2-PC-CA4 due to the short nature of the spacer but 
contrary to this, the compound had similar extinctions coefficients like the other 
compounds. May be the nature of the spacer also has an attribute since there is 
the presence of the tetrazole ring within this chain coupled with the saturated 
alkyl chain. We may conclude that solubility of the conjugates contributed a lot to 
the observed results. 
 























































Table 4: Extinction coefficient at various λmax 
 
3.8.3. Aggregation Tendency 
The fluorescence of the conjugates in DMSO was compared with those in 






the conjugates in DMSO was quite similar except that of FA-PC-CA4 which 
might be attributed to aggregation of the molecule (we have observed the 
reduction in its extinction coefficient above). The decrease in the fluorescence 
intensities of the conjugates in culture media compared to that of the DMSO was 
quite apparent (Figure 22), since they contain the highly lipophilic photosensitizer 
(phthalocyanine). The reduction was quite conspicuous with FA-PC-CA4 
(aggregated most).  The least aggregated of all the conjugates was FA-PEG2K-
PC-CA4 with a long PEG that increases the hydrophilicity of the molecule. 
Although FA-PEG897-PC-CA4 and Biotin-PEG897-PC-CA4 had the same PEG 
lengths, FA-PEG897-PC-CA4 aggregated more in the media than Biotin-
PEG897-PC-CA4. This discrepancy could be attributed the less solubility of FA 
compared to that of biotin. The order of aggregation in culture medium were; FA-
PC-CA4 > FA-PEG2-PC-CA4 > PC-CA4 > FA-PEG897-PC-CA4 > FA-PEG897-
PC-CA4 > FA-PEG2K-PC-CA4. This data suggests that the longer the PEG 
spacer, the more hydrophilic the conjugate becomes and the less prone to form 







Figure 22. Aggregation tendency of various conjugates 
3.8.4. Phototoxicity 
Boc-PEG897-PC-CA4, Biotin-PEG897-PC-CA4 and FA-PEG2K-PC-CA4 all 
selected from in vivo imaging were evaluated against colon 26 cells for in vitro 
studies. Figure 24 shows the phototoxicity of the three conjugates. All three 
conjugates showed similar survival curves.  
3.8.5. Preliminary antitumor efficacy study of FA-PC-CA4 and PC-CA4 
The preliminary antitumor efficacy study in vivo was performed for FA-PC-CA4 
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colon 26 cells were completely suppressed for 9 days by the treatment with PC-
CA4 [dose of 2 µmole/kg in 200 µL cremorphor EL  5 % in PBS, and light of 200 
W/cm2 intensity from a 690 nm diode laser for 30 min] while FA-PC-CA4 showed 
a substantial reduction in the size of the tumor compared to the control group 
(Figure 27). No significant body weight loss was observed from any group 
(Figure 26). (Drs. Pallavi Rajaputra and Bio Moses performed this study.) 
                                
 








     
Figure 25. In vivo PDT efficacy of PC-CA4 treated, FA-PC-CA4 treated and 
conrol group of mice 
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Figure 26. In vivo PDT acute toxicity test on PC-CA4 treated, FA-PC-CA4 





















Figure 27: Pictures of balb/c mice treated with FA-PC-CA4 and PC-CA4  and 
control group  
 
3.8.6. Estimation of cellular uptake of conjugates by confocal fluorescence 
microscopy 
Cellular uptake of the FA-PEG2K-PC-CA4 and Boc-PEG897-PC-CA4 were 
estimated using an Olympus FV 1000 confocal laser scanning microscopy and 
the multi-plate reader. Strong fluorescence of the FA-PEG2K-PC-CA4 was 
observed after treatment for 1.5 h in colon 26 cells, a folate receptor positive cell 
line. (Figure 28) In contrast, the fluorescence of the Boc-PEG 897-PC-CA4 was 
negligible (not bright) suggesting the folate moieties in the folated conjugate 
accelerated its uptake in the colon 26 cells. This may have been expected as 
targeted and non-targeted conjugate were water soluble and the major means of 
transport across the cell membrane would be through folate mediated-
endocytosis for the targeted conjugate while hydrophilic non-targeted conjugate 
could not easily diffuse across cell membrane. This has been attested with the in 
vitro-uptake data that although some random diffusion may occur but that uptake 
was quite negligible. The results showed that these two conjugates had no 






                         
Figure 28. Estimation of cellular uptake by confocal microscopy of Boc-PEG897-
PC-CA4 and FA-PEG2K-PC-CA4 
3.8.7. Cellular uptake  
The cellular uptake of Boc-PEG897-PC-CA4, used as reference in this study FA-
PEG2K-PC-CA4 and Biotin-PEG897-PC-CA4 conjugates as function of 
incubation time was examined at 20 µM concentration. (Figure 29 and 30) 
Summarily within the first 6 h of incubation of the conjugates, the uptake 






conjugates. Compared to the reference conjugate, the uptake of FA-PEG2K-PC-
CA4 was 7-fold higher while that Biotin-PEG897-PC-CA4 was 4-fold within this 
time period. The rapid increase and then followed by a plateau within 6-9 h is not 
strange because the folate recycling rate has been estimated to be 8-12 h 
depending on the cell line.253 Within the saturation period not many receptors are 
available to cause any meaningful change in the uptake rate. At the end of 24 h 
exposure, the uptake of FA-PEG2K-PC-CA4 was 18.8-fold higher than the 
concentration Boc-PEG897-PC-CA4 while the uptake Biotin-PEG897-PC-CA4 
was 4-fold higher than the concentration of Boc-PEG897-PC-CA4. The steady 
increase of the cellular uptake of the conjugates over a 24 h period suggested 
active transport via receptor- mediated endocytosis rather than nonspecific 
absorption. Better results will have been achieved if a folate free medium was 
used in the incubation of the cells. 
 



























             
 
Figure 30. Graphic Representations of the cellular uptake in concentration/M 
3.8.8. Competition Assays. 
The dependence of uptake on the folate or biotin receptor in colon 26 cells was 
evaluated by performing a competitive uptake assay in the presence of excess 
folic acid or biotin (1 mM, 500-fold higher than the conjugates). After 6 h of 
exposure, the accumulation of FA-PEG2K-PC-CA4 and Biotin-PEG897-PC-CA4 
were higher than that of non-targeted conjugate. Figure 31 shows that 1 mM FA 
and I mM biotin significantly reduced the uptake of FA-PEG2K-PC-CA4 and 
Biotin-PEG897-PC-CA4 produgs respectively, but no significant effect was 




























CA4 conjugate was not significantly influenced by the presence of either a 
competitive folic acid or biotin in the medium. While the introduction of excess 
folic acid (500-fold) reduced the uptake of FA-PEG2K-PC-CA4 by 60 %, that of 
excess biotin (500-fold) was reduced by approximately 40 %. The cellular uptake 
study clearly indicates that both the folate and biotin targeted conjugates were 
internalized by folate or biotin receptor-mediated endocytosis, consistent with 
previous reports on folate or biotin receptor-mediated cellular uptake of the folate 
or biotin-conjugated nanocarriers.254 255 Although these compounds were 
synthesized to improve targeting to cancer cells compared to normal tissues or 
cells, some uptake was also observed which suggest that the presence of folic 
acid and biotin could also enhance nonspecific uptake or that better results will 
have been seen had it been a folate free medium was used in the case of folated 
conjugate. 



























Figure 31. Competition Assays of Boc–PEG897-PC-CA4, FA-PEG2K–PC-CA4 
and Biotin-PEG897-PEG-PC-CA4  
3.8.9. In vivo optical imaging 
In order to access the specificity of the conjugates to tumor in vivo optical 
imaging was performed with the following compounds FA-PC-CA4, PC-CA4, FA-
PEG2-PC-CA4, Boc-PEG897-PC-CA4, FA-PEG897-PC-CA4, Biotin-PEG897-
PC-CA4 and FA-PEG2K-PC-CA4 using IVIS imaging system (Caliper Life 
Sciences). Generally, all the targeted conjugates accumulated in the tumor but 
worth noting is the fact some accumulated gradually while others were fast up 
taken by the tumor tissue. We set our exposure time to 0.5 s. Using these 
criteria, three hits were selected for further studies, viz; FA-PEG897-PC-CA4, 
Biotin-PEG897-PC-CA4 and FA-PEG2K-PC-CA4. From Figure 32, FA-PEG2K-
PC-CA4 was fastest to be accumulate with bright fluorescence appearing on 
tumor within the first 3 h and being maximum (peak or brightest fluorescence) at 
7 h time point. Fluorescence reduced gradually after 7 h time point but still a hot 
spot still concentrated at the tumor until after 48 h post injection. It was also 
observed that the conjugate was cleared via the kidney as intensity fluorescence 
from the kidney regions increased with time. Biotin-PEG897-PC-CA4 was the 
second conjugate to be accumulated in the tumor (Figure 33). The accumulation 
of this this was gradual compared to FA-PEG2K-PC-CA4 reaching a maximum 
tumor-to-skin fluorescence between 9-24 h post injections. The difference 






receptors to their respective targeting ligands (folate receptors are known to bind 
folic acid with nanomolar affinity,106 thus, indicating a fast up take when 
compared with biotin receptor(s)). FA-PEG897-PC-CA4 (Figure 34) was the least 
of the conjugates to have brighter fluorescence on tumor. Although FA-PEG897-
PC-CA4 has the same PEG chain lengths like Biotin-PEG897-PC-CA4 and 
similar FA like in FA-PEG2K-PC-CA4 its kinetics were slow but similar to that 
FA-PEG2K-PC-CA4. We observed that FA-PEG897-PC-CA4 compound had 
some solubility issues from the aggregation tendency as a result of PEG chain 
not being long enough to completely solubilize FA conjugated to the PC-CA4 
prodrug in aqueous medium. This could probably explain the difference in in vivo 
optical imaging of FA-PEG897-PC-CA4 which is poorly soluble (aggregates 
more) and Biotin-PEG897-PC-CA4 which is highly soluble in aqueous medium 
although they have the same PEG chain lengths. The exceptional high tumor to 
skin fluorescence when treated with these targeted conjugates can be attributed 
to folate and biotin-mediated targeting of the conjugates to the colon 26 cell lines 
that overexpress both FR-α and biotin receptors. The PC-CA4 conjugate was 
used as one of the standard non-targeted prodrug. From the in vivo images this 
prodrug was not localized compared to the targeted counter-parts. It was 
distributed everywhere within the system (Figure 35). Boc-PEG897-PC-CA4 was 
another non-targeted prodrug used to assess the effect of PEG to the localization 
into the tumor (Figure 36). Boc-PEG897-PC-CA4 showed the high photon counts 
in both tumor and skin with low maximum tumor/skin ratio (~ 1.70) after 72 h post 






From the tumor/ skin photon count ratios the following conclusions could be 
made about the conjugates. 1) Maximum tumor/skin ratio (3.12, 7 h post-IV 
injection) for FA-PEG2K-PC-CA4 was greater than that for FA-PEG897-PC-CA4 
(2.31, 7 h post-IV injection). This may imply that the longer PEG was better. 2) 
The maximum tumor/ skin ratio for FA-PEG897-PC-CA4 was higher than that of 
Boc-PEG897-PC-CA4 (1.36, 7 h post-IV injection). Since both conjugates are 
similar but for the ligand (FA), FA seemed necessary for localization. 3) Biotin-
PEG897-PC-CA4 had higher tumor/skin ratio (3.2, 9 h post-IV injection) than FA-
PEG897-PC-CA4. Both conjugates only differ in their ligands. We may come to 
conclude that biotin (it also showed a slow and decreased clearance rate from 
the tumor) is may be better than FA in targeting for this tumor model, although 
some factors such as solubility of the conjugate may also contribute to the 
observed difference. The longer the PEG length the more soluble the conjugate 
becomes and the higher the accumulation in the tumor compared to the skin or 
normal tissue. This is why conjugates with either no PEG (Figure 37) or shorter 
PEG chain length (Figure 38) showed no significant or little fluorescent 
brightness in the respective tumor accumulation of the conjugates due partly to 



































Figure 34. In vivo images of FA-PEG897-PC-CA4 uptake 
15	  min 1	  h 
3	  h 7	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Figure 36. In vivo images of Boc-PEG897-PC-CA4 uptake  
preinjection 15 min 1 h 
3 h 7 h 9 h 
























We have been able to design multifunctional conjugates of silicon 
phthalocyanine, evaluate the cellular uptake using the confocal microscopy and 
fluorescence from multiplate reader. In vivo uptake using the fluorescence from 
in vivo imaging in balb/c mice inoculated with colon 26 cells was also evaluated 
therefore proving the concept of folate- and biotin-mediated uptake of these 















CHAPTER 4. CONCLUSIONS 
The main goal of this study was to develop a tumor-targeting drug delivery 
system with the capabilities of selectively transport of cytotoxic agents into tumor 
by exploiting overexpressed receptors on malignant cells, and an active or 
remote controlled release of the drug by near infra-red (NIR) light as an 
externally activating agent. A combination of active site-specific targeting and 
site–specific triggering release of an anticancer drug from a drug delivery system 
is expected to increase the local bioavailability of a cytotoxic at the tumor site and 
stands as attractive local treatment to overcome the selectivity problems of 
conventional chemotherapy. Several tumor-targeted delivery vehicles (prodrugs, 
liposomes, dendrimers, micelles, etc.) have been designed, synthesized and 
some are in clinical studies, but most of them lack the active release 
mechanisms within the construct. Although some may be equipped with the 
release mechanism, most of them relied on intrinsic activating agents such as 
enzymes, pH, etc. of the tumor micro-environment. The use of light as an 
extrinsic activating agent looks attractive for the site specific release mechanism, 
but the major hurdle to achieving our aim was to develop a synthetic scheme for 
the vinyl diether linker that was screened in our lab as potential linker to use in 






The electron rich-alkenes activated by heteroatoms have been shown to react 
with singlet oxygen through 1,2-cycloaddition reaction and have been proposed 
for photo – triggerable drug release systems in the form of liposomes, 
cyclodextrin complex and prodrugs. While these linkers and other hetero-olefinic 
bonds appear to be potentially excellent linkers to drug delivery, no facile 
approach to the synthesis have been reported, even though the linkers look very 
simple. Previous methods were limited to symmetric molecules, lengthy steps, 
harsh reaction conditions and low yields. Hence, in collaboration with lab 
colleagues (Drs. Praveen and Bio Moses), we were able to develop new 
synthetic route for O-, N-, and S- vinylation for singlet oxygen labile linkers and 
the kinetic study of the cleavage of these linkers was done.  
To apply our synthetic scheme to biologically active molecule, we set to 
conjugate combretastatin A-4 (CA-4) to core modified porphyrin (CMP) to make 
CA4-L-CMP prodrug linked by the vinyl diether bond, but to our greatest dismay 
the final product was unstable even in an NMR solvent. The intermediates were 
synthesized with great purity and successfully, but the final product, although 
seen as being formed from the TLC pattern, could not be isolated and 
characterized. Owing to the high instability of the prodrug synthesized 
presumably due to the close proximity of the CMP photosensitizer to the electron 
rich double bond, we attempted using a spacer but still failed due to the 
incompatibility of the spacer with the reaction conditions. Moreover, one of the 






steps; hence, drug molecules that carry sensitive functional groups could not be 
used in this scheme.  
With a few problems concerning the vinyl diether linker, we turned our attention 
to an alternative linker (aminoacrylate linker) that was developed in our lab. The 
amino acrylate linker has advantages that could not be met with the vinyl diether 
linker such as easy synthesis, high yields, and mild reaction conditions leading to 
functional group tolerance, and regeneration of parent drugs after cleavage. Dr. 
Bio Moses used this linker to synthesize a prodrug of CA-4 and CMP and the first 
ever prove of the concept of site–specific release mechanism of cytotoxic agent 
both in vitro and in vivo using NIR light. 
With site-specific triggering prodrug concept proven, I set out to synthesize the 
multifunctional prodrug system combining the triggering capabilities to active 
targeting in order to increase local bioavailability of the drug at the tumor site. 
The targeting vector I set was the folic acid and/or biotin whose receptors are 
overexpressed on cancer cells and that are common vitamins required by rapidly 
proliferating tumor cells. The prodrug was envisaged to rapidly accumulate in 
tumor tissue compared to the normal tissue. The prodrug delivery system to be 
synthesized was supposed to be three-in-one tumor targeting system. This 
system consisted of a tumor recognition moiety (FA) that binds to folate receptors 
frequently overexpressed on the surface of malignant cells) linked by a spacer to 
photosensitizer and a cytotoxic warhead (drug) also connected by the 






conjugate that is inactive and sufficiently stable while in circulation; then once 
selectively internalized into cancer cells, cleavage of the conjugate upon 
irradiation with visible light or NIR light restores the active cytotoxic warhead 
(drug). Two of these conjugates were initially synthesized, which consisted of FA-
TPP-CA4 (results not presented in the dissertation) and FA-PC-CA4 by direct 
conjugation of the FA to the photosensitizers. 
From the synthetic point of view, even though the two conjugates can be 
synthesized in principle by straightforward coupling reactions between the 
linkers, FA, CA-4 and photosensitizer, some problems regarding FA-containing 
reaction intermediates must be pointed out. 
- The main hurdle in the synthesis is extreme sensitivity of these reactions 
especially when the drug-linker is attached to the PS. This made it difficult to get 
the high mass of these conjugates from other methods other than the ESI since 
the aminoacrylate linker was being cleaved by laser light used, the inability of 
some of the conjugates to be ionized easily when they are conjugated to FA and 
with molecules above a certain molecular weight range. 
- Secondly, the synthesis of FA-derivatives is represented by very poor solubility 
of all the FA-containing products in organic solvents (except DMSO and DMF). 
On the one hand, this made most of the reaction intermediates unsuitable for 
purification on common solid chromatographic supports. For this reason, 






traces of unreacted reagents and other byproducts. On the other hand, solubility 
problems often resulted in slow reaction rates, both in the coupling of FA with 
various nucleophiles and in the following synthetic steps; this led to low yields 
and, after prolonged reaction times, to the formation of a complex mixture of 
products. Therefore accurate tuning of reaction conditions was considered to 
avoid contamination of reaction products by undesired compounds and thus to 
ensure efficient purification of the desired folate conjugates. 
- Thirdly, the problem was also in the characterization of the final products. Due 
to high instability, the high mass could not be determined using other mass spect 
methods except ESI. The final molecules seemed to be completely ablated by 
laser light used in MALDI, FAB, etc. The low volatility of FA conjugates above a 
certain mass range made the analysis difficult (above 1800 the signal for the 
internal standards are always too low to get the molecular ion peak). Concerning 
the problem of mass, SUNY at Buffalo is developing a method for the 
determination of the masses of these unstable molecules. NMR of FA conjugates 
are poorly resolved, which has thus led to alternative methods of characterization 
such as UV, IR, etc. 
Despite all the challenges faced in the synthesis, preliminary in vitro test (figure 
U) conducted on the first conjugate (FA-PC-CA4) synthesized by direct reaction 
of the FA to the photosensitizer indicate that it was not accumulating in the colon 
26 cell line. When we investigated the behavior of this conjugate in cell culture 






aggregating, and that is why their fluorescence was completely quenched, and it 
was stacked in the medium (due to its ampiphilicity) and not taken up by cells. 
The NMR this conjugate (FA-PC-CA4) was not good, which indicated the 
aggregation even in DMSO as the most polar NMR solvent in use. We decided to 
pursue the modification of the PC4 core by sequentially increasing its solubility 
by varying the PEG chain length. Interestingly, the first modification with short 
PEG could not improve the solubility, but after adding a longer spacer of 
approximately 2000 Da, the conjugate showed marked uptake by the cells. It is 
noteworthy that the effect of PEG lengths on target ability of the FA has been 
investigated by several research groups on the receptor-mediated uptake of 
nano-particulate conjugates such as liposomes, micelles but not with the prodrug 
delivery systems and photosensitizers. With FA-PEG2K conjugates being non-
monodisperse polymers, we decided to synthesize prodrugs of FA and biotin with 
pure (>95 %) PEG (897 Da).  The prodrugs showed good uptake in the cell 
culture medium. The best of the conjugates was FA-PEG2K-PC-CA4 followed by 
Biotin-PEG897-PC-CA4 and lastly FA-PEG897-PC-CA4. With all the seven 
conjugates synthesized, we decided to assess the accumulation in mice tumor 
models using in vivo imaging. Interestingly, FA-PEG2K-PC-CA4 showed the best 
accumulation with fluorescence peaking between 3 to 7 h post injections followed 
by the biotin conjugate (Biotin-PEG897-PC-CA4) with fluorescence peaking 
between 9 to 24 h post-injection. FA-PEG897-PC-CA4 had the similar kinetic like 
that of FA-PEG2K-PC-CA4, but the uptake was not all that great compared to 






test using both the confocal microscopy and cellular accumulation with a multi-
plate reader at every time point. Finally using the competition assays we were 
able to demonstrate folate- and biotin-mediated uptake of these conjugates. We 
were able to achieve 19 fold cellular accumulations in the cells after 24 h of 
incubation of our folate prodrugs while that of the biotin was 4 folds compared to 
the standard compound Boc-PEG897-PC-CA4. Uptake accumulations of folate 
prodrug were done in normal medium having some folic acid. This indicates that 
we would have achieved better results had a folate free medium been used.256 I 
was able to design, synthesize and demonstrate the concept of folate or biotin 
mediated uptake of our prodrug using PEG of various chain lengths to solubilize 
the highly hydrophobic PC molecules. Although folate active targeting has been 
used in other delivery vehicles such as liposomes, micelles, nanoparticulate 
delivery systems, the use of active targeting on the drug or prodrug is more 
appealing than targeting the macromolecules since there is always an issue of 
the stability of these polymers in circulation. To best of my knowledge very little 
has done in the development of drug delivery system the can actively target and 
actively release the carried payload using NIR light. Moreover our prodrugs 
function as multimodal drug delivery system performing the following functions: 
1) Imaging (diagnostic application) 
2) PDT agent 
3) Targeting agent due folate or biotin attached 






To the best of our knowledge, the systems developed so far may constitute only 
three of the above four functions as theranostic agents, which thereby indicates 
the importance of our prodrug delivery system. Because of the high expression of 
folate receptors and biotin receptors in most cancer cell lines such as ovarian, 
breast, lung, etc., our prodrugs will definitely find good use not only in the 
treatment of aggressive solid tumors such as those mentioned above (ovarian 
and breast cancer especially) but in the delivery of bioactive molecule. In vivo 
PDT is underway to determine the efficacy of these prodrugs to treat bigger 
tumors although the non-targeted analog (Figure Z) has proven to be quite 
effective in our lab. 
 
 
1H- NMR (upper) and 13C-NMR (lower) spectra of the compounds 





















































































































































































Table 3. Kinetic data of oxidation of olefins. 
 Remaining Starting Compound (%) Observed Product (%) 
Time 
(min) control 6 8 11 Ca (6a+6b)/2* 8a 8b 
0 100 100 100 100 0 0 0 0 
5 38 26 29 27 0 53 67 32 
10 11 2 0 0 1 87 99 48 
15 0 0 0 0 2 92 99 48 
* In 1H-NMR, the formate peaks of expected products of 6 (6a and 6b) were too close. 
Thus, two peaks were integrated together and divided by 2. 
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Figure 50: Kinetic NMR spectra of 8 
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Figure	  57:	  1H	  NMR	  of	  FA-­‐PC-­‐CA4	  






































































































































Figure 65: NMR of Biotin-PEG-PC-CA4  
 
 

































































Figure 69: NMR of Boc-PEG897-PC-CA4 
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